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DIABETES MELLITUS (DM) is a complex multisystemic 
metabolic disorder characterized by a relative or absolute insufficiency of 
insulin secretion and/or concomitant resistance to metabolic action of 
insulin on target tissues.
1
 The two predominant forms of DM are known as 
Type I or Insulin Dependent Diabetes Mellitus (IDDM) and Type II or             
Non–Insulin Dependent Diabetes Mellitus (NIDDM) 2. NIDDM accounts 
for more than 90% of the diagnosed cases of DM
2
. Globally 140 million 
people are estimated to have DM. It is estimated that there will be over 230 
million people with DM by the year 2010, and half of this population will be 
in Asia
3
. The number of people with diabetes in India currently around 40.9 
million is expected to rise to 69.9 million by 2025 unless urgent preventive 
steps are taken
4
. This metabolic disease is a burden on both patients and 
society because of the high morbidity and mortality associated with 
infections and renal, retinal and vascular complications. Primary prevention 
of the disease and the prevention of diabetic complications are of great 
practical importance
5
.  
 SALIVA is a complex fluid, whose important role is to maintain the 
well being of the oral cavity
6
. 1000 to 1500 ml of saliva is secreted per day 
and is approximately about 1ml/min. Parotid gland (PG) contributes to 
about 25% of the saliva while Submandibular (SSG) 70% and Sublingual 
(SLG) 5% respectively. Mixed saliva from all the glands is slightly acidic 
with a pH of 6.35-6.85 and is hypotonic to plamsa. Mixed saliva contains 
about 99% water and 1% solids. The remaining 1% consists of most part of 
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the large organic molecules inclusive of proteins, glycoproteins, lipids, 
small organic molecules like glucose, urea and electrolytes
6
. Saliva plays 
many important roles in the oral cavity. It helps in preparation of food for 
swallowing, helps in appreciation of taste, plays a role in digestion, has 
cleansing and protective functions, plays an important role in speech, and 
regulates the body temperature and the water balance. Parotid glands 
produce a watery secretion. Submandibular gland and sublingual gland 
produces more viscous fluid than parotid gland
7
. The importance of well 
functioning salivary glands for oral health is well known.  
The composition and secretion of saliva is influenced by local as 
well as systemic, hormonal, nutritional and metabolic factors.
7
 Diabetes 
Mellitus which is known to alter the constiution and flow of saliva
8
. 
Although differences in the output and composition of saliva from Diabetic 
and Non Diabetic subjects have been observed in a number of studies, many 
of these findings have been contradictory. 
Saliva offers some distinctive advantage. Whole saliva can be 
collected non-invasively and by individuals with limited training. However, 
studies pertaining to the use of saliva as a non invasive tool in monitoring 
blood glucose levels in Diabetic patients have been done predominantly in 
the Western population.
9,10
 
This study is an attempt to Estimate and Correlate the Salivary 
Glucose concentration and Serum Glucose concentration in Diabetics and 
healthy controls in a Chennai Population. 
Aims & Objectives 
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AIM:  
Comparison of Salivary Glucose and Serum Glucose concentration 
in Non-Insulin Dependent Diabetes Mellitus patients. 
OBJECTIVES: 
1.  To estimate the Salivary Glucose and Serum Glucose concentration 
in Non-Insulin Dependent Diabeties Mellitus patients. 
2. To estimate the Salivary Glucose and Serum Glucose concentration 
in Healthy control group. 
3. To correlate these Salivary Glucose and Serum Glucose 
concentrations in Non Insulin Dependent Diabeties Mellitus patients 
and Healthy controls. 
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A review of Diabetes Mellitus and Saliva are being presented here.  
DIABETES MELLITUS  
Diabetes Mellitus (DM) is a disease of glucose, fat, and protein 
metabolism resulting from impaired insulin secretion, varying degrees of 
insulin resistance, or both
11
. Hyperglycemia is the most clinically important 
metabolic aberration in DM and the basis for its diagnosis. Apart from the 
obvious impact of impaired glucose metabolism, DM and chronic 
hyperglycemia are associated with important ophthalmic, renal, 
cardiovascular, cerebrovascular, and peripheral neurological disorders
12
.  
CLASSIFICATION OF DIABETES MELLITUS 
Most cases of DM can be classified as Type 1, formerly, known as 
Insulin-Dependent Diabetes Mellitus (IDDM) and Type 2 formerly, known 
as Noninsulin-Dependent Diabetes Mellitus (NIDDM). Blood glucose 
elevation that does not satisfy the definition of Type-1 or Type-2 DM is 
classified as impaired glucose tolerance or impaired fasting glucose. 
Secondary forms of DM also exist. For example, diseases of the pancreas, 
such as pancreatitis, may produce a state of absolute insulin deficiency. 
Numerous drugs may create a Diabetic state, glucocorticoids being the most 
notable. Glucocorticoids not only increase insulin resistance in liver and 
muscle, but also impair the response of pancreatic beta cells to elevated 
plasma glucose
12
. Recognition of secondary forms of DM is important 
because removal or management of the underlying cause can reverse the 
Diabetic condition. Another form of DM is Gestational Diabetes or DM 
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presenting during pregnancy which is the result of insulin production 
insufficient to overcome insulin resistance produced by placental anti-
insulin hormones like estrogen, prolactin or cortisol
12
. 
EPIDEMIOLOGY OF DIABETES IN INDIA 
Mohan et al
4 
reviewed the epidemiology of Type 2 Diabetes in the 
Indian scenario. The authors explained that India leads the world with 
largest number of Diabetic subjects earning the dubious distinction of being 
termed the “Diabetes capital of the world”. According to the Diabetes 
Atlas
13
 published by the International Diabetes Federation, the number of 
people with Diabetes in India currently around 40.9 million is expected to 
rise to 69.9 million by 2025 unless urgent preventive steps are taken. The so 
called “Asian Indian Phenotype” refers to certain unique clinical and 
biochemical abnormalities in Indians which include increased insulin 
resistance, greater abdominal adiposity i.e., higher waist circumference 
despite lower body mass index, lower adiponectin and higher high sensitive 
C-reactive protein levels
4
. This phenotype makes Asian Indians more prone 
to Diabetes and premature coronary artery disease
4
. The most disturbing 
trend is the shift in age of onset of Diabetes to a younger age in the recent 
years. Early identification of at-risk individuals would greatly help in 
preventing or postponing the onset of Diabetes and thus reducing the burden 
on the community and the nation as a whole
4
. 
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REGULATION OF BLOOD GLUCOSE 
Diabetes has an impact on a number of fundamental metabolic 
processes. Glucose homeostasis is the result of the relative influences of two 
opposing hormones, insulin and glucagon
14
. Insulin is a protein synthesized 
in the pancreatic beta cells. It exerts its biochemical effects by interacting 
with transmembrane cellular receptors. The principal role of insulin is to 
facilitate storage of glucose as glycogen, free fatty acids as triglycerides, 
and amino acids as protein
15
. Insulin also inhibits the breakdown of 
glycogen, lipids, and protein. Furthermore, insulin inhibits ketogenesis and 
gluconeogenesis. Insulin therefore has its most important effect on muscle 
and adipose tissues and on the liver. Glucagon supports opposing activity by 
stimulating glucose and fatty acid formation, ketogenesis, and conversion of 
amino acids to glucose
12
. Following a meal, plasma insulin increases, 
altering the relative activity of insulin and glucagon in favor of insulin. As a 
result, dietary carbohydrate is stored in muscle and liver in the form of 
glycogen. Free fatty acids are converted to triglycerides in fat and amino 
acids are converted to protein. As plasma glucose returns to its preprandial 
value, so too does insulin secretion, and the preprandial insulin/glucagon 
ratio is reestablished. The sensitivity of target tissue to insulin is an 
important determinant of insulin effect. Feedback mechanisms increase 
insulin release in individuals who are relatively insulin resistant and 
decrease insulin release if there is increasedtissue sensitivity
12
. Target-tissue 
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insulin sensitivity plays an important role in the pathophysiology of Type-2 
DM. 
ETIOLOGY
 
 In both the common types of DM, enviromental factors interact with 
genetic susceptibility to determine which people develop the clinical 
syndrome and the timing of its onset. However, the underlying genes, 
precipitating enviromental factors and pathophysiology differ substantially 
between Type 1 and Type 2. Type 1 is invariably associated with profound 
insulin deficiency requiring replacement therapy. Type 2 retains the capacity 
to secrete some insulin but exhibit impaired sensitivity to insulin and can 
usually be treated without insulin repalcement therapy. However, upto 20% 
of patients with Type 2 Diabetes ultimately develop profound insulin 
deficiency requiring replacement therapy.
11 
PATHOPHYSIOLOGY OF TYPE-1 DIABETES 
Rossini AA et al
16
 characterized Type-1 DM by an absolute insulin 
deficiency brought about by the Autoimmune destruction or accelerated 
disappearance of pancreatic beta cells. However, some patients have no 
evidence of an Autoimmune mechanism. Libman IM et al
17
described such 
patients to have Type-1B DM. Martin S et al
18
described mononuclear 
lymphocytic infiltrates, principally T lymphocytes and Eisenbarth et al
19 
identified them in pancreatic islets in individuals with Type-1 DM. Littorin 
B et al
20
 identified autoantibodies to a number of beta-cell antigens can be 
in the sera of those with Type-1 DM. Such autoantibodies can be detected 
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well in advance of the onset of clinical Diabetes and in some first-degree 
relatives of individuals with Type-1 DM. Riley WJ et al
21 
realised that, high 
autoantibody titers in relatives of Diabetics are harbingers of the 
development of Clinical Diabetes within a few years. Feutren Get al
22 
said 
that novel Immunosuppressive treatment of recently diagnosed Type-1 DM 
can decrease or even eliminate the need for exogenous insulin 
administration. 
However, the potential toxicity of continuous immunosuppressive 
therapy precludes its clinical application in DM treatment. Susceptibility to 
Type-1 DM is inherited and the principle gene associated with this genetic 
predisposition is the Major Histocompatability Complex (MHC) on 
chromosome 6. Davies JL et al
23 
found out that a number of HLA genes 
have been implicated in the familial clustering of Type-1 DM. Atkinson 
MA et al
24 
said that a life-long risk of developing Diabetes is 6% in 
offspring and 5% in siblings of affected individuals. Apart from the 
underlying role of genetics, environmental factors are also believed to play 
an important role in the pathogenesis of Type-1 DM. Dahlquist GG et al
25 
said that several pregnancy and perinatal factors, such as maternal age >25 
years, preeclampsia, neonatal respiratory disease, and jaundice, have been 
associated with the development of Type-1 DM. Szopa TM et al
26 
study 
revealed that viral infection has also been implicated in the destruction of 
beta cells or as a trigger for the production of autoantibodies. Genuth SM et 
al
27 
found out that the pancreas has a substantial reserve for insulin 
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production and clinical DM does not occur until 90% of beta cells have been 
eliminated. The end result of an absolute insulin deficiency is impaired 
glucose uptake by muscle and fat as well as a loss of insulin-induced 
suppression of liver glucose production. Genuth SM et al
28 
found out that 
FPG may rise to 300 to 400mg/dl and Post-prandial levels as high as 500 to 
600mg/dl. This produces an osmotic diuresis with polyuria and, 
subsequently, increased thirst. Plasma fatty acid levels increase as does 
hepatic uptake of free fatty acids. This in turn, leads to increased production 
of ketoacids and metabolic acidosis which is known as Diabetic 
Ketoacidosis
12
. Weight loss occurs as a result of protein catabolism and 
lypolysis. 
PATHOPHYSIOLOGY OF TYPE-2 DIABETES 
Kahn CR et al
29
 said that the pathophysiology of Type-2 DM is 
complicated by the fact that patients present with varying degrees of both 
insulin deficiency and insulin resistance. Boden G et al
30 
said that in 
contrast to Type-1 DM, hyperglycemia in Type-2 DM is principally a result 
of insulin resistance. Cavaghn MK et al
31
 said that the eventual loss of the 
ability of the pancreas to increase insulin output, in the setting of insulin 
resistance, creates a relative insulin deficiency and progression to 
established Type-2 DM. Hyperglycemia itself may contribute to insulin 
deficiency through a toxic effect on pancreatic beta cells. The practical 
implication of this complex interaction between insulin resistance and 
insulin production is that any clinical measure taken to normalize plasma 
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glucose will improve glucose homeostasis. Although adverse effects on fatty 
acid metabolism are seen, in contrast to Type-1 DM, there is usually 
sufficient residual insulin secretion in Type-2 DM to limit ketoacid 
formation and prevent the development of clinical acidosis. Groop LC et 
al
32 
said that some Type-2 Diabetics also manifest pancreatic islet-cell 
autoantibodies typical of Type-1 DM and experience a more rapid decline in 
beta-cell function than those without autoantibodies. In contrast to Type-1 
DM, genetics significantly influence the development of Type-2 DM. 
Benett PH et al
33 
found out that the lifetime risk for a first-degree relative 
of an affected individual is 5 to 10-fold the risk in an age and weight-
matched population without a family history of DM. Mokdad AH et al
34 
said that obesity, especially of long duration, is an important risk factor for 
the development of Type-2 DM. Chan JM et al
35
 said that abdominal 
obesity (waist >102 cm in men, >88 cm in women), in particular, is an 
important risk factor for Type-2 DM and is associated with insulin 
resistance. Type-2 DM is often accompanied by other conditions in addition 
to obesity. These include hypertension, elevated serum low-density–
lipoprotein cholesterol, low serum high-density–lipoprotein cholesterol. 
DeFronzo RA et al
36 
said that the clustering of metabolic risk factors for 
both Type-2 DM and Cardiovascular disease has prompted the diagnosis of 
„„Metabolic Syndrome‟‟.Eckel RH et al37 said that the Metabolic Syndrome 
is considered a pro-inflammatory, prothrombotic state that is a significant 
predictor of Type-2 DM and Cardiovascular Disease. 
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CLINICAL FEATURES 
 Diabetes can affect almost every system in the body. Examination of 
the patient with Diabetes is focused on hands, blood pressure, eyes, insulin 
injection sites and feet
11
. Examination of the hands may show limited joint 
mobility. There is presence of painless stiffness in the hands and it 
occassionally affects the wrists and shoulders. Dupuytren‟s contracture is 
common in Diabetes and may include nodules or thickening of the skin and 
knuckle pads
11
. Carpal tunnel syndrome is common in diabetics and 
presents with wrist pain radiating into the hands. A trigger finger may also 
be present at times. Muscle wasting or sensory changes may be present as 
features of a peripheral sensorimotor neuropathy, though more commonly 
seen in the lower limbs
11
. Eyes show impaired visual acuity and cataract or 
lens opacification eventually
11
. Insulin injection sites show bruising, lumps, 
subcutaneous fat deposition and erythema. Look for evidence of callus 
formation on weight bearing areas, clawing of the toes, loss of the plantar 
arch, discoloration of the skin, localised infection and presence of ulcers
11
. 
Fungal infection may affect skin between toes and nails. There is usually 
weight loss in IDDM and obesity in NIDDM. 
ORAL MANIFESTATIONS OF DIABETES MELLITUS 
GrossiS et al
38
, Tsai C et al
39
, Taylor GW et al
40
 and Karjalainen 
KM et al
41 
said that independent of the severity of plaque accumulation 
there will be presence of gingivitis with gingival bleeding, periodontitis, and 
periodontal bone loss with DM, especially when poorly controlled. Marked 
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mobility of teeth and generelised attrition is an important hallmark of 
Diabetes. Defects in immune status, altered bacterial flora, and 
microvascular disease are the postulated pathogenesis of Diabetic 
periodontal disease
42
. Iacopino et al
43 
said that evidence also indicates that 
bacteremia associated with periodontitis contributes to insulin resistance and 
destruction of pancreatic islet cells. Diabetic patients may complain of dry 
mouth. Xerostomia may be a manifestation of hyperglycemia-associated 
dehydration or impaired salivary gland function
44
. Oral candida infections 
occur with greater frequency in poorly controlled Diabetics.
45 
INVESTIGATIONS
 
 Testing urine for glucose is a common procedure for detecting 
Diabetes, using sensitive glucose specific dipsticks
11
. Tesing should be 
performed on urine passed 1-2 hours after a meal since this will detect more 
cases of Diabetes than a fasting specimen. Glycosuria always warrants a 
further assessment by blood testing. The greatest disadvantage of using 
urinary glucose as a diagnostic screening procedure is the indiviual variation 
in renal threshold for glucose
11
. The most common cause of glycosuria is a 
low reanl threshold which is common in young people and during 
pregnancy
11
. Estimation of the blood glucose concentration, using an 
accurate laboratory method rather than a side-room technique is therefore 
essential in making the diagnosis.  
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 Ketone bodies can be indentified by the nitroprusside reaction, 
which is primarily specific for acetoacetate
11
. The test is conveniently 
carried out using tablets or dipsticks for ketones. Ketonuria may be found in 
people fasting or exercising strenuously for long periods, who have been 
vomitting repeatedly, or who have been eating a diet high in fat and low in 
carbohydrate
11
. Ketonuria is therefore not pathognomic of diabetes but if 
associated with glycosuria, the diagnosis of Diabetes is highly likely. In 
Diabetic Ketoacidosis, ketones can be detected in plasma using dipsticks. 
 Dipstick testing for albumin is a standard procedure to identify the 
presence of renal disease in people with Diabetes. This will detect urinary 
albumin greater than 300mg/dl
11
. Smaller amounts of urinary albumin can 
be measured and these provide indictors of the risk for developing Diabetic 
nephropathy and/or macrovascular disease.  
Laboratory glucose testing in blood relies upon enzymatic reaction 
and is cheap, usually automated and highly reliable. However, variation in 
blood glucose depends on whether the patient has eaten recently
11
. Blood 
glucose can be measured with colorimetric or other testing sticks, which are 
often read with a portable electronic meter. These finger pricks are used for 
capillary testing to monitor Diabetes treatment.  
Glucose concentration are lower in venous than in arterial or 
capillary blood. Whole blood glucose concentrations are lower plasma 
concentrations because red blood cells contain relatively little glucose
11
. In 
general, venous plasma values are the most reliable for diagnostic purposes.  
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Glycalated hemoglobin provides an accurate and objective measure 
of glycemic control over a period of weeks to months
11
. This can be utilized 
as an assessment of glycaemic control in a patient with known Diabetes, but 
is not sufficiently sensitive to make a diagnosis of Diabetes and is usually 
within the normal range in patients with Impaired Glucose Tolerance. 
In Diabetes, the slow non-enzymatic covalent attachment of glucose 
to haemoglobin (glycation) increases the amount in the HbA1 or HbA1c 
fraction relative to non – glycated adult hemoglobin (HbA0)
11
. This fraction 
can be separated by chromatography, laboratories may report glycated 
hemoglobin as total glycated hemoglobin (GHb), HbA1c. The rate of 
formation of HbA1c is directly proportional to the ambient blood glucose 
concentration, a rise of 1% in HbA1ccorresponds to an approximate average 
increase of 2mmol/l in blood glucose
11
. Although HbA1c concentration 
reflects the integrated blood glucose control over the lifespan of the 
erythrocyte that is 120 days, half of the erythrocytes are replaced in 60 days 
and HbA1c is weighted by changes in glycemic control occuring in the 
month before measurement
11
. As HbA1c is affected more by recent than by 
earlier events, a large shift in blood glucose control is rapidly accompanied 
by a change in HbA1c, detectable with in 2-3 weeks. 
Various assay methods can be used to measure HbA1c, precluding 
direct comparison of HbA1c values between laboratories. HbA1c estimates 
may be erroneously diminished in anemia or during pregnancy and may be 
difficult to interpret with some assay methods in patients who have anemia 
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or a hemoglobinopathy
11
. HbA1c is usually measured once or twice a year to 
assess glycaemic control, permitting appropriate changes in treatment and 
identifying inconsistency with the patient‟s record of home blood glucose 
monitoring
11
. HbA1c also provides an index of risk of developing Diabetic 
complications.   
Glycated serum protein can be measured and because of their shorter 
half life, give an indication of glyacemic control over the preceeding 2 
weeks.  
The concentration of serum lipids – total choloestrol, low density 
and high density lipoprotein (LDL and HDL) cholestrol and triglyceride, is 
yet another important index of overall metabolic control in Diabetic patients 
and should be measured at diagnosis and regularly thereafter
11
. Ideally, the 
triglyceride concentration should be measured in the fasting state.  
DIAGNOSIS
 
 Symptoms of hyperglycemia include thirst or dry mouth, polyuria, 
polydypsia, polyphagia, nocturia, tiredness, fatigue, recent changes in 
weight, blurring of vision, pruritus vulvae, balanits (genital candidiasis), 
nausea, headache, prediliction for sweet foods, mood change, irritability, 
difficulty in concentrating and apathy
11
. 
 When Diabetes is suspected, the diagnosis may be confirmed by a 
random blood sugar concentration greater than 11.0mmol/l or 199mg/dl. 
When random blood glucose values are elevated but are not diagnostic of 
Diabetes, glucose tolerance is usually assessed by either fasting 
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bloodglucose estimation or by the oral glucose tolerance test (OGTT)
11
. In 
oral glucose the patients is asked to follow an unrestricted carbohydrate diet 
for three days before the test. The patient should be fasting overnight atleast 
for 8 hours. The patient is asked to rest for 30 mins before the test, with no 
smoking and should be seated for duration of test. The plasma glucose is 
measured before and 2 hours after 75 g of glucose load.  
 The diagnostic criteria for Diabetes Mellitus recommended by 
World Health Organization suggests that
11
 
A. If a patient complains of symptoms suggesting diabetes 
a. Test urine for glucose and ketones 
b. Measure random or fasting blood glucose. Diagnosis 
confirmed by 
i. Fasting plasma glucose ≥ 126 mg/dl 
ii. Random plasma glucose ≥ 200 mg/dl. 
B. Indications for oral glucose tolerance test in a Diabetic 
i. Fasting plasma glucose 110-126 mg/dl 
ii. Random plasma glucose 140-199mg/dl 
HbA1c is not used for diagnosis.   
COMPLICATIONS OF DIABETES 
Clark CM et al
46 
found out that the chronic elevation of plasma 
glucose leads to increased intracellular accumulation of glucose and its 
metabolic products. Nathan DM et al
47 
found out that resulting long-term 
complications include microvascular disease of the eye namely retinopathy 
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and nephropathy and a variety of neuropathies. Diabetic retinopathy occurs 
in all forms of DM with the earliest manifestations being retinal 
microaneurysms. With progression, affected vessels become occluded and 
retinal infarctions follow. Vessel proliferation can lead to vitreous 
hemorrhage, fibroproliferative changes with retinal traction, and vision loss. 
Diabetic nephropathy affects 30% of patients with Type-1 DM and 4% to 
20% with Type-2 DM
48
. Beginning as thickening of the capillary basement 
membrane, deposition of protein ultimately leads to glomerulosclerosis, 
impaired renal function, and progression to renal failure. If a person does 
not develop nephropathy after having Diabetes for 25 to 30 years, then it is 
unlikely he or she will develop the condition
49
. This is unlike Diabetic 
retinopathy, where risk continuously increases over time. Diabetic 
neuropathy has many possible manifestations
49
. The most common 
presentation is symmetrical altered sensation in the toes and feet. A minority 
of patients experience a painful, burning character to the neuropathy. Motor-
nerve involvement is less common but may involve both cranial and 
peripheral nerves. Cranial nerve neuropathies may present with extraocular 
muscle weakness and double vision.  
Finally, involvement of the autonomic nervous system can affect 
gastric motility, erectile function, bladder function, cardiac function, and 
vascular tone. Cardiovascular disease occurs with greater frequency in 
Diabetics than in the general population. 75% of Type-2 Diabetics die of 
cardiovascular disease
50
. As noted, Type-2 Diabetics with the metabolic 
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syndrome have a clustering of risk factors for cardiovascular disease. The 
prevalence of coronary artery disease in Type-2 DM with the metabolic 
syndrome is twice that in individuals without Diabetes or Metabolic 
Syndrome
51
. Coronary artery disease develops at an earlier age in Diabetics, 
and atypical anginal symptoms and congestive heart failure are a more 
common presentation
52
.  
Haffner SM et al
51
discovered that the risk of a first myocardial 
infarction in patients with DM is equal to that of recurrent infarction in 
nondiabetics. Though some disagree, it is generally held that Diabetes with 
poor plasma glucose control is associated with an increased risk of infection. 
Neutrophil adherence, chemotaxis, phagocytosis and bactericidal activity, 
and cell-mediated immunity are all compromised in the hyperglycemic 
diabetic
53,54
. The plasma glucose threshold for such granulocyte dysfunction 
is in the range of 198 to 270mg/dL
55
. Both granulocyte and T-cell 
dysfunction are reversed by the administration of insulin
56,57
. The practical 
implication of Diabetic-associated immune dysfunction is that optimal 
control of plasma glucose is important both in the prevention of infection 
and in the management of established infection.  
SALIVA 
The most commonly used laboratory diagnostic procedures involve 
the analyses of the cellular and chemical constituents of blood
7
. Other 
biologic fluids are utilized for the diagnosis of disease, and saliva offers 
some distinctive advantages. Whole saliva can be collected non-invasively, 
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and by individuals with limited training. No special equipment is needed for 
collection of the fluid. Diagnosis of disease via the analysis of saliva is 
potentially valuable for children and older adults, since collection of the 
fluid is associated with fewer compliance problems as compared with the 
collection of blood
7
. Further, analysis of saliva may provide a cost-effective 
approach for the screening of large populations. 
DIAGNOSTIC APPLICATION OF SALIVA 
Saliva can be considered as gland-specific saliva and whole saliva. 
Gland-specific saliva can be collected directly from individual salivary 
glands: parotid, submandibular, sublingual, and minor salivary glands
7
. 
Navazesh et al
58 
realised that secretions from both the submandibular and 
sublingual salivary glands enter the oral cavity through Wharton's duct, and 
thus the separate collection of saliva from each of these two glands is 
difficult. The collection and evaluation of the secretions from the individual 
salivary glands are primarily useful for the detection of gland-specific 
pathology, i.e., infection and obstruction. However, whole saliva is most 
frequently studied when salivary analysis is used for the evaluation of 
systemic disorders. 
Whole saliva or mixed saliva is a mixture of oral fluids and includes 
secretions from both the major and minor salivary glands, in addition to 
several constituents of non-salivary origin, such as gingival crevicular fluid 
(GCF), expectorated bronchial and nasal secretions, serum and blood 
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derivatives from oral wounds, bacteria and bacterial products, viruses and 
fungi, desquamated epithelial cells, other cellular components, and food 
debris
59
.  
Saliva can be collected with or without stimulation. Stimulated 
saliva is collected by masticatory action i.e., from a subject chewing on 
paraffin or by gustatory stimulation, i.e. application of citric acid on the 
subject's tongue
60
. Stimulation obviously affects the quantity of saliva; 
however, the concentrations of some constituents and the pH of the fluid are 
also affected. Unstimulated saliva is collected without exogenous gustatory, 
masticatory, or mechanical stimulation. Unstimulated salivary flow rate is 
most affected by the degree of hydration, but also by olfactory stimulation, 
exposure to light, body positioning, and seasonal and diurnal factors
7
. The 
best two ways to collect whole saliva are the draining method, in which 
saliva is allowed to drip off the lower lip, and the spitting method, in which 
the subject expectorates saliva into a test tube
61
. Saliva has protective 
properties and contains a variety of antimicrobial constituents and growth 
factors
62
. In addition, saliva has lubricating functions and aids in the 
digestion of food
60
. 
The salivary glands are composed of specialized epithelial cells, and 
their structure can be divided into two specific regions: the acinar and ductal 
regions. The acinar region is where fluid is generated and most of the 
protein synthesis and secretion takes place
7
. Amino acids enter the acinar 
cells by means of active transport, and after intracellular protein synthesis, 
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the majority of proteins are stored in storage granules that are released in 
response to secretory stimulation
63
. Three models have been described for 
acinar fluid secretion. These three models include the active transport of 
anions into the lumen and passage of water according to the osmotic 
gradient from the interstitial fluid into the salivary lumen. The initial fluid is 
isotonic in nature and is derived from the local vasculature. While acinar 
cells are water-permeable, ductal cells are not. However, ductal cells 
actively absorb most of the Na
+
 and Cl
-
 ions from the primary salivary 
secretion and secrete small amounts of K
+
 and HCO3
-
 and some proteins. 
The primary salivary secretion is thus modified, and the final salivary 
secretion as it enters the oral cavity is hypotonic
64
. The autonomic nervous 
system that is the sympathetic and parasympathetic controls the salivary 
secretion. The signaling mechanism involves the binding of 
neurotransmitter primarily acetylcholine and norepinephrine to plasma 
membrane receptors and signal transduction via guanine nucleotide-binding 
regulatory proteins (G-proteins) and activation of intracellular calcium 
signaling mechanisms
64
.  
There are several ways by which serum constituents that are not part 
of the normal salivary constituents like drugs and hormones can reach 
saliva. Within the salivary glands, transfer mechanisms include intracellular 
and extracellular routes. The most common intracellular route is passive 
diffusion, although active transport has also been reported. Ultrafiltration, 
which occurs through the tight junctions between the cells, is the most 
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common extracellular route
65,66
. In contrast, a serum molecule reaching 
saliva by diffusion must cross five barriers: the capillary wall, interstitial 
space, basal cell membrane of the acinus cell or duct cell, cytoplasm of the 
acinus or duct cell, and the luminal cell membrane
66
. Serum constituents are 
also found in whole saliva as a result of GCF outflow. Depending on the 
degree of inflammation in the gingiva, GCF is either a serum transudate or, 
more commonly, an inflammatory exudate that contains serum constituents.  
Some systemic diseases affect salivary glands directly or indirectly, 
and may influence the quantity of saliva that is produced, as well as the 
composition of the fluid. These characteristic changes may contribute to the 
diagnosis and early detection of these diseases. 
Saliva can be analyzed as part of the evaluation of endocrine 
function. Insulin can be detected in saliva, and salivary insulin levels have 
been evaluated as a means of monitoring serum insulin levels. A positive 
correlation between saliva and serum insulin levels following a glucose 
tolerance test was reported for healthy subjects, Non-Insulin-Dependent 
Diabetic patients, and obese Non-Diabetic patients
67
. Similarly another 
study found a better correlation between salivary and serum insulin levels in 
93 healthy subjects
68
. As assessed by radioimmunoassay, a glucose 
tolerance test performed on nine healthy patients produced a positive 
correlation between salivary and serum insulin levels. Salivary insulin levels 
reached maximal values approximately 30 minutes after the serum levels; 90 
minvs. 60min
69
. Other investigators also reported a similarly high 
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correlation between salivary and serum insulin levels in healthy individuals 
and Insulin-Dependent Diabetic patients, but proposed that the use of 
salivary insulin levels for the evaluation of serum insulin levels could be 
misleading, since significant discrepancies between salivary and serum 
insulin levels were detected for several individuals
70
. Additional studies are 
required to determine if salivary insulin levels should be used for the 
evaluation of serum insulin levels. 
In general, serum and salivary levels of protein hormones are not 
well-correlated. These hormones are too large to reach saliva by means of 
passive diffusion across cells or by ultrafiltration, and the detection of these 
hormones in saliva is primarily due to contamination from serum through 
GCF or oral wounds.  
Salivary monitoring has many advantages over the more 
conventional serum analysis. Multiple saliva samples can be collected in a 
relatively short time interval, which makes the non-invasive collection of 
saliva ideal for this purpose.
71
 These factors have to be considered when 
saliva is evaluated as an alternative for the evaluation of serum levels. 
For accurate diagnosis, a defined relationship is required between the 
concentration of the biomarker in serum and the concentration in saliva. 
Normal salivary gland function is usually required for the detection of 
salivary molecules with diagnostic value. Salivary composition can be 
influenced by the method of collection and the degree of stimulation of 
salivary flow. Changes in salivary flow rate may affect the concentration of 
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salivary markers and also their availability due to changes in salivary pH. 
Variability in salivary flow rate is expected between individuals and in the 
same individual under various conditions. In addition, many serum markers 
can reach whole saliva in an unpredictable way. These parameters will 
affect the diagnostic usefulness of many salivary constituents
72
. 
Furthermore, certain systemic disorders, may affect salivary gland 
function and consequently the quantity and composition of saliva. Whole 
saliva also contains proteolytic enzymes derived from the host and from oral 
micro-organisms
73
. These enzymes can affect the stability of certain 
diagnostic markers. Some molecules are also degraded during intracellular 
diffusion into saliva. Any condition or medication that affects the 
availability or concentration of a diagnostic marker in saliva may adversely 
affect the diagnostic usefulness of that marker. Despite these limitations, the 
use of saliva for diagnostic purposes is increasing in popularity. Several 
diagnostic tests are commercially available and are currently used by 
patients, researchers, and clinicians.  
Due to its many potential advantages, salivary diagnosis provides an 
attractive alternative to a noninvasive, time consuming, complicated, and 
expensive diagnostic approaches
7
. However, before a salivary diagnostic 
test can replace a more conventional one, the diagnostic value of a new 
salivary test has to be compared with accepted diagnostic methods. The 
usefulness of a new test has to be determined in terms of sensitivity, 
specificity, correlation with established disease diagnostic criteria, and 
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reproducibility. It is difficult to interpret the significance of a single report 
that examines levels of any particular marker
7
. However, due to the many 
potential limitations of salivary diagnosis, promising results from pilot 
studies must be confirmed in larger, well-controlled trials. While many 
questions remain, the potential advantages of salivary analysis for the 
diagnosis of systemic disease suggest that further studies are warranted. 
Definition of specific disorders that can be identified or monitored by the 
analysis of saliva offers the possibility of improved patient management. 
 Consequently, an increased utilization of saliva as a diagnostic fluid 
could be seen. 
Sreedevi et al
71 
estimated and correlated the salivary and serum 
glucose concentration in Diabetics and healthy controls. They included 60 
newly diagnosed Type 2 Diabetic patients and 60 age and sex matched 
control subjects in their study. Blood and saliva samples from both the 
groups were collected at least two hours after breakfast. For the 
experimental group the samples were collected once again after the control 
of Diabetes. A highly significant correlation was found between salivary 
glucose and serum glucose before the treatment and also after the control of 
Diabetes. The correlation between the salivary glucose and serum glucose 
was also highly significant in the control group. The levels of salivary 
glucose did not vary with age and sex. In control group the salivary glucose 
ranged from 0.7 to 1.3% and the mean was 1.0 ± 0.1mg%. In the study 
group, before the treatment of Diabetes the salivary glucose ranged from 1.5 
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to 8.0mg% and the mean was 3.10 ± 1.04mg%. After the control of 
Diabetes, the salivary glucose ranged from 0.6 to 1.8mg% and the mean was 
1.1 ± 0.2mg%. The comparison of salivary glucose before treatment and 
after control of Diabetes was done by using paired t-test as same samples 
were examined twice and difference was statistically highly significant that 
is P<0.001. Unpaired t-test was used to compare the Diabetic and control 
groups and the difference was statistically significant that is P<0.01. In 
control group the serum glucose ranged from 61 to 167mg% and the mean 
was 105.7 ± 22.3mg%. In study group, before the treatment of Diabetes, the 
serum glucose ranged from 205 to 490mg% and the mean was 309.5 ± 
68.2mg%. After the control of Diabetes the serum glucose ranged from 71 
to 167mg% and the mean was 119.7 ± 27.5mg%. The comparisons of serum 
glucose before treatment and after control of Diabetes was done by using 
paired t-test as same samples were examined twice and the difference was 
statistically highly significant that is P <0.01. The coefficient correlation r 
value for salivary and serum glucose in controls was +0.74. The value was 
found to be statistically highly significant that is P<0.001. The correlation 
coefficient value for salivary and serum glucose before the treatment of 
Diabetes was +0.67 and r value for salivary and serum glucose after 
Diabetes is bought under control was +0.66. The values were found to be 
statistically highly significant before the treatment of Diabetes and also after 
the control of diabetes wit a P<0.001. Salivary and serum glucose was 
correlated before the treatment of Diabetes and after the control of Diabetes 
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and also in control group in different age groups. It was observed that there 
was no significant correlation between different age and sex groups and 
salivary and serum glucose that is p<0.05. Hence, the authors concluded that 
there was a significant correlation between serum glucose and salivary 
glucose; salivary glucose holds the potential of being a marker in Diabetes. 
With a further added advantage of being a non invasive preocedure with no 
need of special equipments and with fewer compliance problems as 
compared with collection of blood. 
Sashikumar et al
72 
evaluated a total of 150 individuals between 40 
and 60 years of age. 100 Diabetes Mellitus Type 2 were recruited and 
another 50 individuals without Diabetes were recruited. The subjects were 
divided into 3 groups. Group I consisted of 50 individuals with controlled 
Diabetes determined by random non fasting plasma glucose (RNFPG) 
values between 120mg/dl and 200mg/dl. Group II included 50 subjects with 
uncontrolled Diabetes determined by RNFPG values above 200 mg/dl. 
Group III was the control group without Diabetes with RNFPG 80 to 
120mg/dl and was age and gender-matched with groups I and II. Subjects 
were recruited when presenting for routine follow-up, at which time blood 
samples were obtained for measuring glucose and glycosylated hemoglobin 
levels. One week later, subjects returned for delivery of a whole saliva 
sample and a second sample of blood.Such whole salivary samples represent 
fluids contributed by secretions from major and minor salivary glands and 
potentially, gingival crevicular fluid. Unstimulatedsalivary glucose (USSG) 
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levels were significantlyhigher in both uncontrolled and controlled Diabetes 
compared with Non Diabetes. Both SSG and USSG levels were 
significantly correlatedwith RNFPG in the entire study population. Only 
among those with uncontrolled Diabetes were SSG and USSG levels 
significantly correlated with RNFPG. It was concluded that although the 
concept of using salivary instead of blood glucose is intriguing, it does not 
seem to be biologically feasible, as the association between salivary and 
plasma glucose levels is not unambiguously established. 
Hegde et al
73 
performed a study to explore the potential of saliva as 
a diagnostic tool  in which 26 Type 2 Diabetes patients were compared with 
21 age matched Non-Diabetic healthy controls for Fasting plasma glucose 
(FPG) and salivary glucose (SG). Significantly high FPG with a p = 0.005 
was found. FPG showed positive correlation to SG with r = 0.410 only in 
diabetes. Since SG levels did not differ between the two groups. Overall 
salivary glucose concentration showed no significant difference between 
two groups implying association of high plasma glucose with high SG levels 
to be an infrequent observation which may be affected by metabolic control 
of the disease. Significant positive correlation of FPG with SG in Diabetics 
further supports this aspect. It was concluded that conventional marker 
like FPG is a better indicator of glycemic status. 
Veena et al
74 
undertook a study in an attempt to compare and 
correlate glucose levels in saliva and serum of patients with Diabetes and 
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Non-Diabetic healthy individuals, to determine the efficacy of saliva as a 
diagnostic aid. They screened 250 individuals visiting Diabetic clinics 
randomly. Of these, 200 were confirmed Type 2 Diabetics and were under 
medication. The remaining 50 gave neither a past history of Diabetes nor 
did their present glycemic status depicted high values. Venous blood and 
salivary samples were obtained from each individual and subjected to 
glucose estimation. Both fasting and post-prandial samples were analyzed. 
In the study, glucose was detected in the saliva of both Diabetic and         
Non-Diabetics. The fasting salivary glucose values in the control group 
ranged from 4.1 to 13.3mg/dl and the postprandial salivary glucose values 
from 12.5 to 20.0mg/dl. The fasting salivary glucose values in the study 
group ranged from 4.1 to 26.6mg/dl and the Post-prandial salivary glucose 
values from 15.3 to 30.7mg/dl. It was observed that as blood glucose levels 
changed in both fasting and post-prandial samples, so did salivary glucose 
levels, irrespective of age and sex. A significant p value of <0.001 and 
positive correlation was found between blood glucose and salivary glucose 
levels in both the Diabetics and the controls. The authors concluded that 
saliva can be used as an adjunct diagnostic tool in Diabetes Mellitus. 
 S. SathyaPriya et al
75 
studied a total of 60 patients, comprising 60 
Type 2 Diabetic patients and 25 healthy controls for estimation of glucose in 
saliva, in order to aid in reaching firm conclusions about their alterations in 
Diabetics as compared to helathy Non Diabetics and to compare and 
correlate these parameters in Uncontrolled and Controlled Diabetics. 
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Salivary investigations were performed using unstimulated whole Saliva. A 
significant correlation was found between salivary and blood concentrations 
in the Diabetes.Mean salivary glucose levels were found to be significantly 
elevated in uncontrolled Diabetics when compared to healthy non-Diabetics. 
There was significant increase in mean salivary amylase, protein & 
potassium in Diabetic patients when compared to healthy Non-Diabetics. 
Furthermore, in this study the protein profiles of whole saliva of Diabetic 
and healthy Non-Diabetic were compared. The saliva from Diabetic patients 
appeared to have more of proline-rich protein bands. These findings 
suggested that saliva can be used reliably for reflecting and monitoring the 
blood glucose concentration in the patients of Diabetes Mellitus. 
Cedric et al
76
 evaluated salivary glucose concentration and 
excretion in unstimulated saliva in both normal and Type 2 Diabetic 
subjects. The authors found that in normal subjects, a decrease in saliva 
glucose concentration. The glucose concentration averaged 79.4 ± 5.8μM in 
unstimulated saliva in normal subjects. The glucose concentration averaged 
187.3±20.0μM in unstimulated saliva of the Diabetics.  The glucose 
concentration failed to differ significantly in male and female Diabetic 
patients. The glucose concentration in unstimulated saliva was about twice 
higher in the Diabetic patients (187.3 ± 20.0μM) than in the control subjects 
(79.4 ± 5.8μM). In the latter patients, as compared to control subjects, the 
relative magnitude of the increase in saliva glucose concentration was 
comparable, however, to that of blood glucose concentration. These findings 
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confirm the poor link between glycaemia and glucose concentration in 
saliva, atleast on an individual basis. 
CampbellM.J.A. et al
77 
in their study used two methods to analyse 
the saliva of non-diabetic and Type 2 Diabetic patients for glucose content. 
Using the Somogyi blood glucose estimation technique, glucose was 
detected only in the saliva of Diabetic patients. Blood glucose estimations 
were conducted on the same patients and no degree of correlation between 
blood glucose and salivary glucose could be demonstrated. Using 
Chromatographic techniques, spot tests, and an ultramicro-technique, 
glucose was found to be present in the saliva of both the Non-Diabetic and 
the Diabetic patient. At the same time other sugars were detected in the 
saliva of both groups of patients, namely galacturonic acid, glucuronic acid, 
lactose, maltose, sucrose, fructose, mannose, sorbose and arabinose, and a 
relationship between the coincident presence or absence of these sugars was 
calculated. A quantitative analysis of the glucose content showed that in 
those cases which reacted positively the glucose values for the Non-
Diabetic lay between 0.24 and 3.33mg/100ml and for the Diabetic between 
0.44 and 6.33mg/100ml. 
Darwazeh et al
78 
estimated the glucose concentration in 
unstimulated mixed saliva and serum was assayed and correlated with oral 
candidal colonization in 41 Type 2 Diabetic and 34 healthy control subjects. 
A statistically significant result was found, in Diabetic patients and it was 
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found that the salivary glucose concentration was significantly higher than 
in the controls and was directly related to blood glucose concentration.  
Michael W. J. Dodds et al
79
 studied whether improvements in the 
level of Diabetic control in a group of subjects with poorly controlled         
Non-Insulin-Dependent Diabetes Mellitus influence salivary  composition. 
Repeated whole unstimulated saliva was collected from Diabetic patients 
attending an outpatient Diabetes education program and a matched          
Non Diabetic control group. Saliva was analyzed for composition. Subjects 
reporting taste alterations had higher mean blood glucose levels than 
subjects with normal taste sensation. They concluded that poorly controlled 
Non Insulin Dependent Diabetes Mellitus has no influence on saliva output, 
although amylase activity may be elevated, and there may be taste 
alterations 
Amer et al
80 
estimated the salivary and blood glucose concentrations 
in Non Diabetic healthy individuals and patients with Type 2 Diabetes 
Mellitus. Glucose could not be detected in the salivary samples obtained 
from the Non Diabetic control subjects whose random serum glucose 
concentrations were significantly higher (p<0.005) than the serum glucose 
concentrations of the Non Diabetic control subjects. Glycosylated 
haemoglobin A1c was also determined in the patients and a significant 
correlation with r = 0.82 was found between HbAlc and serum glucose 
concentrations in these patients, indicating that these patients had average 
elevated blood glucose concentration over anextended time period. Glucose 
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was only found in the saliva of patients with Diabetes Mellitus, while the 
salivary samples of age matched non-diabetic subjectsdid not show the 
presence of glucose. A significant correlation of r = 0.78 was found between 
salivary and blood concentrations in the Diabetics. This finding suggests 
that saliva can be used reliably for reflecting and monitoring the blood 
glucoseconcentration in the patients of Diabetes Mellitus. 
Suleyman Aydin et al
81
 examined the relationship between active 
(aGAH) and inactive (dGAH) ghrelin in the saliva and other salivary 
parameters in Type II Diabetic patients and healthy controls. Salivary 
parameters were assessed in a single measurement of unstimulated whole 
saliva from 20 obese and 20 non-obese Type II Diabetes patients, and in 22 
healthy controls. Saliva aGAH and dGAH levels were measured using a 
commercial radioimmunoassay kit. Salivary concentrations of aGAH and 
dGAH ghrelin were more markedly decreased in obese Diabetic subjects 
than in the two other groups. Salivary glucose (200%) levels were 
significantly higher in obese Diabetic subjects than in controls (p <.005); 
and salivary glucose (192%) levels in Non-obese Diabetic subjects were 
also significantly higher than those ofcontrol. Salivary glucose levels in the 
obese Diabetic subjects were almost the same. Glucose levels were higher in 
diabetic subjects than in controls. Furthermore, there were correlations 
between GAH levels and BMI, and between GAH and blood pressure. 
These results indicate that saliva can be used as a valuable diagnostic aid in 
the relationship to other salivary parameters. 
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 Meurman et al
82  
investigated and studied the organic constituents 
of whole saliva in relation to autonomic nervous function in patients with 45 
patients with  mean age, 68± 6 years Non-Insulin-Dependent Diabetes and 
77 control subjects (mean age, 67 ± years).. Resting whole saliva samples 
were collected and analyzed. There were no statistically significant 
differences between patients with Diabetes and control subjects in the 
organic constituents of saliva. They concluded that saliva secretion might be 
more affected by autonomic nervous dysfunction in patients with Non-
Insulin-Dependent Diabetes than in Non Diabetic control subjects 
Nakamoto et al
83 
examined blood and saliva samples to see if there 
is a correlation between saliva glycated protein and blood glycated protein. 
Blood and saliva samples of 51 male workers were collected. They were 
divided into groups as control, and Diabetics. The fructosamine 
andhydrazine methods were used to measure saliva glycated protein. 
HbA1c, fructosamine and blood glucose were measured as indices of blood 
glycated protein, and the correlation between blood glycated protein and 
saliva glycated protein was examined. It was found that the saliva 
fructosamine glycated protein showed a significant correlation with HbA1c 
and blood glucose with a r = 0.449; p = 0.001 and r = 0.445; p = 0.001, 
respectively. No correlation was identified between saliva hydrazine 
glycated protein and the index of blood glycated protein. It was concluded 
that the blood glycated protein and blood glucose could be estimated by 
measuring saliva glycated protein. 
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Eliaz Kaufman et al
7 
reviewed the diagnostic applications of saliva. 
In the review they examined the diagnostic application of saliva for 
systemic diseases. As a diagnostic fluid, saliva offers distinctive advantages 
over serum because it can be collected non-invasively by individuals with 
modest training. Furthermore, saliva may provide a cost-effective approach 
for the screening of large populations. Gland-specific saliva can be used for 
diagnosis of pathology specific to one of the major salivary glands. Whole 
saliva, however, is most frequently used for diagnosis of systemic diseases, 
since it is readily collected and contains serum constituents. These 
constituents are derived from the local vasculature of the salivary glands and 
also reach the oral cavity by the flow of gingival fluid. Analysis of saliva 
may be useful for the diagnosis of hereditary disorders, Autoimmune 
diseases, Malignant and Infectious diseases, and Endocrine disorders, as 
well as in the assessment of therapeutic levels of drugs and the monitoring 
of illicit drug use. 
Maria-Sueli-Marques Soares et al
84 
investigated and studied the 
concentration of salivary glucose in healthy individuals and compared it 
with the capillary glycemia. Samples of unstimulated whole saliva were 
collected from 63 Non-Diabetic patients. The concentration of salivary 
glucose and capillary blood was measured in all of the patients. The salivary 
glucose was determined by enzymatic method and spectrophotometry. The 
data was then analyzed and they found that the whole sample consisted of 
47.6% males and 52.4% women, with an average age of 37.5±15.7yrs old.  
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The average blood glucose among the males studied was 100.05±13.51 
mg/dl, and among females, it was 99.5± 13.9mg/dl. The average salivary 
glucose for the whole sample was 5.97± 1.87mg/dl, with 5.91± 2.19mg/dl 
among males and 5.97± 1.56mg/dl among females, respectively without any 
significant differences with p = 0.908.The concentration of salivary glucose 
did not present any statistically significant correlation with the capillary 
glycemia with p = 0.732. They concluded that the concentration of salivary 
glucose is not dependent on capillary glycemia and that the concentration of 
salivary glucose does not present significant differences between the 
measurements for males and females. 
Bennett CM et al
85 
assessd the validity of glycated haemoglobin 
A1c (HbA1c) as a screening tool for early detection of Type 2 Diabetes. 
They performed a systematic review of primary cross-sectional studies of 
the accuracy of HbA1c for the detection of Type 2 Diabetes using the oral 
glucose tolerance test as the reference standard and fasting plasma glucose 
as a comparison. They found 9 studies met the inclusion criteria. At certain 
cut-off points, HbA1c had slightly lower sensitivity than fasting plasma 
glucose (FPG) in detecting Diabetes, but slightly higher specificity. For FPG 
at a cut-off point of ≥ 6.1mmol/l, the sensitivity ranged from 48 to 64% and 
specificity from 94 to 98%. Both HbA1c and FPG have low sensitivity for 
the detection of impaired glucose tolerance. It was concluded that HbA1c 
and FPG are equally effective screening tools for the detection of Type 2 
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Diabetes. The HbA1c cut-off point of >6.1% was the recommended 
optimum cut-off point for HbA1c in most reviewed studies; however, there 
is an argument for population-specific cut-off points as optimum cut-offs 
vary by ethnic group, age, gender and population prevalence of Diabetes. It 
was concluded that the current cost of HbA1c is higher than FPG, the 
additional benefits in predicting costly preventable clinical complications 
may make this a cost-effective choice. 
Mostafa S.A. et al
86 
examined the potential impact of the preferred 
use of HbA1c as a diagnostic tool on the prevalence and phenotype of 
T2DM. They analysed the Leicester Ethnic Atherosclerosis and Diabetes 
Risk (LEADER) cohort for previously undiagnosed individuals between 40 
and 75 years of age who had OGTT repeated if within the Diabetes range, 
and HbA1c results. They then compared the prevalence and phenotype of 
subjects with T2DM based on either HbA1c ±6.5% or OGTT using 1999 
World Health Organization criteria. It was found that from the total 
population of 8696, they detected 291 (3.3%) with T2DM from using an 
OGTT, and 502 (5.8%) had HbA1c ≥6.5%. Of those diagnosed with T2DM 
by OGTT, 93 (1.2%) had HbA1c <6.5% and therefore would not have been 
classiﬁed as having T2DM using proposed criteria. Using HbA1c criteria 
resulted in 304 (3.5%) additional cases of T2DM, approximately doubling 
the prevalence. Of these 304 additional people, 172 (56.7%) had impaired 
glucose tolerance⁄impaired fasting glycaemia according to 1999 World 
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Health Organization criteria. Using HbA1c criteria there was an increase of 
2.2 and 1.4-fold in south Asians and white Europeans detected, respectively. 
It was concluded that introducing HbA1c ±6.5% as the preferred diagnostic 
test to diagnose T2DM signiﬁcantly increased numbers detected with 
T2DM; however, some people were no longer detected as having T2DM. 
Materials and Methods 
 
39 
 
STUDY TOPIC 
 “Comparison of Salivary Glucose and Serum Glucose concentration 
in Non-Insulin Dependent Diabetes Mellitus patients”. 
STUDY DESIGN  
 This is a Case Control type of study. 
STUDY DURATION 
 This study was conducted between March 2010 and April 2011 in 
the Out Patient Department of Voluntary Helath Services, Adyar, Chennai. 
STUDY POPULATION 
 A total number of 80 patients were involved in the study. 
OBTAINING APPROVAL FROM THE AUTHORITIES: 
 Permission from the ethical committee of Ragas Dental College 
and Hospital, Chennai and Voluntary Health Services, Adyar, Chennai 
was obtained before starting the study.   
 Due consent to participate in the study was obtained from the 
Subjects in letter format both in Tamil and English. 
MATERIALS 
Collection of Saliva Sample:  
 A pair of sterile gloves 
 Disposable mouth mask. 
 Sterile plastic containers for collection of saliva. 
 Refrigerator 
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Collection of Blood Sample: 
 Disposable 5ml plastic syringe and 23 gauge needle 
 Vacutainer coated with Ethylene diamine tetra acetic acid 
(EDTA) 
 Torniquet 
 Sterile Cotton 
 70% alcohol as surface disinfectant 
 Sterile vials 
 Refrigerator 
Equipments: 
 Centrifuge for separating plasma from blood 
 Semiautoanalyzer (Biosystems BTS-310 Photometer) 
 Micro pipette 
METHODOLOGY 
STUDY GROUP: 
 The study group comprised of a total number of 80 patients. Out of 
the 80 patients, 40 were Healthy controls and the other 40 were suffering 
from Type 2 Diabetes Mellitus. 
GROUP I 
 This study group comprised of 40 Healthy Non Diabetic indiviuals 
visiting the Out Patient Department at Voluntary Health Services.  
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Clinical SelectionCriteria: 
 Individuals who are apparently healthy with no history of Diabetes, 
Hypertension and any known systemic diseases. 
 Indiviuals with Fasting blood sugar of 125mg/dl or below. 
 Indiviuals with Random blood sugar level of 200mg/dl or below. 
GROUP II 
 This study group comprised of 40 patients suffering from Type 2 
Diabetes Mellitus visiting the Out Patient Department at Voluntary Health 
Services. 
Clinical Selection Criteria: 
 30 diagnosed Diabetic patients with Type 2 Diabetes Mellitus. 
 Patients with fasting blood sugar level of 126mg/dl and above. 
 Patients with Random blood sugar level of 200mg/dl and above 
INFORMED CONSENT: 
 Permission from the ethical committee of Ragas Dental College 
and Hospital, Chennai and Voluntary Health Services, Adyar, Chennai 
was obtained before starting the study.   
 Informed consent was taken from all subjects before including them 
in the study.  
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EXCLUSION CRITERIA: 
 Participants with infectious diseases during one month before saliva 
sampling, active dental abcesses, and collagen vascular diseases were 
excluded from the study. 
EXAMINATION OF THE SUBJECTS: 
 The experimental subjects were made to sit comfortably on a chair. 
Relevant demographic data was collected.An Intra Oral examination is 
carried out. Whole unstimulated saliva is collected. Saliva samples are 
collected in sterile test tubes, immediately transferred aseptically to sterile 
tubes and frozen on dry ice and alcohol. The samples are stored in styroform 
boxes containing dry ice and carried to a freezer where they are left until 
time of assessment of the salivary glucose and serum glucose. 
SERUM SAMPLE COLLECTION
87
: 
 Blood samples are taken from the vein in the antecubital fossa. The 
tourniquet is set around the upper arm of the subject, search for the proper 
vein by inspecting and palpating and then sterilize the injection site. The 
vein can be anchored by placing the thumb about two centimeters below the 
vein and pulling gently to make the skin a little taut. After that, the needle, 
beveled upward, should be pushed smoothly and quickly into the vein, to 
minimize the possibility of hemolysis as a result of vascular damage. 
Immediately after the insertion, the tourniquet should be released to 
minimize the effect of hemoconcentration. 5 ml of venous blood was drawn 
and the serum was separated by centrifugation, supernatant was aspirated. 
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The samples were centrifuged no later than 30 minutes after the sample was 
drawn.EDTA and Sodium Fluoride were added to prevent the coagulation of 
blood.All samples were centrifuged at 3000 rpm for 10 min to remove 
particulate materials and the clean supernatant was proessed immediately 
for estimation of glucose. 
SALIVA SAMPLE COLLECTION
7
: 
 The subjects were required to abstain from eating for atleast 8 hours. 
Drinking, smoking or using oral hygiene products was not allowed for at 
least 1 hour before saliva collection. The patients were asked to rinse their 
mouth with water and were made to sit comfortably in a chair.Whole 
unstimulated saliva amounting to 5ml was collected for 5-minutes by 
spitting method. This was pooled saliva and represented the output from all 
the salivary glands. 
 All samples were centrifuged at 3000 rpm for 10 min to remove 
particulate materials and the clean supernatant was proessed immediately 
for estimation of glucose. 
GLUCOSE ESTIMATION (GOD- POD Method, End Point)
87,88 
INTRODUCTION 
 Glucose is the reducing monosaccharide that serves as the principal 
source of cellular energy in the body. It enters into the cell under the 
influence of insulin and undergoes a series of chemical reactions to produce 
energy. Lack of insulin or resistance to its action at the cellular level causes 
Diabetes.Therefore, in Diabetes Mellitus the blood glucose level are very 
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high. However, high blood glucose level is also observed in the pancreatitis, 
pituitary or thyroid dysfunction, renal failure and liver disease whereas low 
glucose level is associated with starvation, hyperinsulinaemia, neopalasms 
or insulin induced hypoglycemia. Estimation of glucose in serum as well as 
saliva was done with this method. 
PRINCIPLE
89 
 Glucose is oxidized by glucose oxidase (GOD) to produce gluconate 
and hydrogen peroxide. The hydrogen peroxide is then oxidatively coupled 
with 4 amino- antipyrene (4-AAP) and phenol in the presence of peroxidase 
(POD) to yield a redquinoeimine dye that is measured at 505nm. The 
absorbance at 505 nm is proportional to concentration of glucose in the 
sample. 
  Glucose +2H2O + O2                    Gluconate + H2O2 
  2H2O + 4-AAP + Phenol   Quinoeimine Dye 
 Absorbance of the colored solution is directly proportional tothe 
glucose concentration, when measured at 505nm. 
REAGENT COMPOSITION 
Reagent 1: 
Glucose Oxidase 20000 u/l 
Peroxidase 1200 u/l 
4-AAP 0.246 mmol/l 
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Reagent 2: 
Glucose Standard 100 mg/dl 
 
PRECAUTIONS 
 Avoid ingestion, do not pipette by mouth. 
 Avoid contact with skin and eyes. If spilled, thoroughly wash 
affected area with water. 
 Flush with plenty of water while disposing. 
 
REAGENT  
 Reagent should be clear. Turbidity and/or precipitation may be 
because of reagent deterioration. 
SAMPLE COLLECTION AND STORAGE 
 Unhaemolysed serum isto be used for the testing. EDTA and sodium 
fluoride were the preferred anti-coagulant. Freshly collected samples for 
assay. 
GENERAL ASSAY PARAMETERS 
Mode End Point 
Wavelength (nm) 505 
Wavelength Range Usable(nm) 500-550 
Blank with Reagent 
Sample Volume (µl) 5/10 
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Reagent R1 (µl) 500/1000 
Incubation Time (min) 15 /7 
Incubation Temperature (°C) RT/37 
Normal Low (mg/dl) 70 
Normal High (mg/dl) 110 
Linearity (mg/dl) Upto 500 
Standard Conc. (mg/dl) 100 
Units mg/dl 
 
PROCEDURE 
 One reagent blank and one standard were used for each assay series. 
Pipette into Test Tubes: 
Particulars Blank Standarad Sample 
Reagent 1 1000µL 1000µL 1000µ 
Distilled Water 10µL - - 
Reagent 2 - 10µL - 
Sample - - 10µL 
 
 Mix well & incubate for 15 min at room temperature or 7 min at 
37
o
C. Measure the absorbance of standard (A std) and sample (A sample) 
against reagent blank at 505 nm. 
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CALCULATION 
Glucose concentration is calculated using the following formula:  
STATISTICAL ANALYSIS: 
All the datas were entered in Microsoft excel sheets.  Statistical analysis was 
done using SPSS software SYSTAT version 7.0. 
             Mean and standard deviation were estimated in the sample for each 
study group.  Mean values were compared by using one-way ANOVA 
followed by multiple range tests by Tukey-HSD for multiple group 
comparison and students „t” test and chi square test  for two group 
comparison. 
In the present study p <0.05 was considered as the level of significance.  
                            Mean (X) =  ∑ Xi 
          n 
      
Where Xi is the individual observation and n is the sample size. 
ANOVA: 
    Variation between observed group averages 
 F Ratio=             -------------------------------------------------- 
      Variation within each group 
 Students “t” test (unpaired) 
t=difference in means/standard error of difference 
 
Standard Deviation      =  
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RAGAS DENTAL COLLEGE AND HOSPITAL 
2/102 East Coast Road, Uthandi, Chennai – 600019 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
 
CASE SHEET PROFORMA 
A. GENERAL INFORMATION 
S.No:     O.P.No:  Date: 
 
1. Name: 
2. Age: 
3. Sex:    1. Male   2. Female: 
4. Occupation: 
a. Unemployed 
b. Skilled 
c. Professional 
d. Administration 
e. Trade/Business 
f. Student 
5. Address: 
 
Materials and Methods 
 
49 
 
 
6. Income; 
a. <Rs. 1,000/month b. >1,000-5,000/month  
c. >5,000/month 
B. History: 
1. History relating to Diabetes Mellitus 
a. Age at diagnosis of Diabetes Mellitus 
b. Onset and duration of Diabetes 
c. Family history of Diabetes Mellitus 
2. Presence of any other systemic disease 
a. Present   b. Absent 
 If yes, specify 
3. History of medication; 
a. Yes   b. No 
If yes, specify Duration    Name of medicine  
 
INVESTIGATION 
1. Random Blood Sugar 
2. Salivary Glucose Estimation 
3. Fasting Blood Sugar 
4. Post Prandial 
                                       Figures 
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Figure 1. Armamentarium for Clinical Examination 
 
 
Figure 2. Autoclave  
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Figure 3. Centrifuge 
 
 
 
Figure 4. Armamentarium for Serum Glucose and Salivary Glucose Estimation 
 
 
 
 
 
 
 
 
                                       Figures 
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Figure 5. Serum Glucose and Salivary Glucose Estimation kit 
 
 
Figure 6. Oral Rinse Procedure 
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 The present study is a Case Control study which was conducted in 
the Out Patient Department of Voluntary Health Services, Adyar, Chennai. 
It was devised to estimate the Salivary Glucose and Serum Glucose level in 
Type 2 Diabetes Mellitus patients and Healthy Controls. The study was 
conducted between March 2010 and April 2011 with 40 Type 2 Diabetes 
Mellitus patients and 40 Healthy controls.The data obtained from the study 
was statistically analysed. The results extracted were compared with various 
variables included in the study and are presented here. 
Table 1:  Sex wise distribution of subjects in Group I (Healthy 
Controls) 
The study consisted of a total number of 80 subjects.  This table 
denotes the Sex wise distribution of subjects in Group I. Out of the 80 
subjects, 40 were included in Healthy Controls (Group I) among whom 16 
males were present, accounting for 40% of the group and 24 females 
accounting for 60% of the group. A significant p value of <.005 was found.  
Table 2: Sex wise distribution of subjects in Group II (Type 2 Diabetes 
Mellitus) 
This table denotes the Sex wise distribution of subjects in Group II, 
40 subjects were included in Type 2 Diabets Mellitus (Group II) among 
whom 16 were males accounting for 40% of the population and 24 were 
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females accounting for 60% of the population. A significant p value of 
<.005 was found. 
Table 3: Age wise distribution of subjects in Group I (Healthy Controls) 
This table denotes the Age wise distribution of subjects in Group I. 
The Age of the subjects included in the study ranged between 28-75 yrs. 
Among the 40 subjects in Group I, 04 (10%) were below 35yrs, 09 (22.5%) 
were between 36-45yrs, 13 (32.5%) were between 46-55yrs and finally 14 
subjects (35%) were above 55yrs. A significant p value of <.005 was found. 
Table 4: Age wise distribution of subjects in Group II (Type 2 Diabetes 
Mellitus) 
This table denotes the Age wise distribution of subjects in Group II. 
The Age of the subjects included in the study ranged between                       
28-75 yrs. Among the 40 subjects in Group II, 04 (10%) were below 35yrs, 
09 (22.5%) were between 36-45yrs, 13 (32.5%) were between 46-55yrs and 
14 (35%) were above 55yrs. A significant p value of <.005 was found. 
Table 5: Age and Sex wise distribution of subjects in GroupI (Healthy 
Controls) 
This table shows the distribution of subjects based on Age and Sex 
in Group I. The Age range was from 28 to 75yrs with the mean age of        
50.97 yrs. In the below 35yrs age group there were totally 4 subjects 
inwhich accounted for 10.0% of the total subjects in the group, with 1 male 
(6.3%) and 3 females (12.5%) of the total number of males and females 
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present in the group. Similarly the 36-45yrs age group had 9 subjects in 
them accounting for 22.5% of the entire group population with 5 males 
(31.3%) and 4 females (16.7%) of the total males and females present in the 
group. The 46-55yrs age group comprised of totally 13 patients or 32.5% of 
the entire group with 5 males (31.3%) and 8 females (33.3%). And finally, 
the age group above 55yrs comprised of totally 14 patients or 35% of the 
entire group with 5 males (31.3%) and 9 females (37.5). There is a clear 
female predilection of 26 (60%) compared to the males who accounted for 
14 (40%) of the population in the total sample size of 40 patients. A 
significant p value of <.005 was found. 
Table 6: Age and Sex wise distribution of subjects in GroupII (Type 2 
Diabetes Mellitus) 
This table shows the distribution of subjects based on Age and Sex 
in Group II. The Age range was similar to that of Group I with variation 
between 28 to 75yrs with the Mean Age of 50.97 yrs. The subjects below 
35yrs age group totally had 4 subjects in them which accounted for 10.0% 
of the total subjects in the group, with 1 male (6.3%) and 3 females (12.5%) 
of the total number of males and females present in this group. Similarly,in 
the 36-45yrs age group, there were 9 subjects in them accounting for 22.5% 
of the entire group population with 5 males (31.3%) and 4 females (16.7%) 
of the total males and females present in the group. The 46-55yrs age group 
comprised totally of 13 patients or 32.5% of the entire group with 5 males 
(31.3%) and 8 females (33.3%). And finally the Age group above 55yrs 
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comprised of totally 14 patients or 35% of the entire group with 5 males 
(31.3%) and 9 females (37.5). There is a clear female predilection of 26 
(60%) compared to the males who accounted for 14 (40%)in the total of 40 
patients. A significant p value of <.005 was found. 
Table 7: Salivary Glucose level distribution according to Sex in Group I 
(Healthy Controls) 
This table shows the distribution of subjects based on Salivary 
Glucose levels and Sex in Group I. The Salivary Glucose levels varied from 
0–8mg/dl in this group. Totally there were 40 patients among the 
distribution of 16 males and 24 females. Out of these there were totally 4 
subjects ie. 10.0% of the Group I who had a Salivary Glucose level of 
0mg/dl out of which 2 were males and 2 were females accounting for 12.5% 
and 8.3% respectively of the total number of males and females present in 
this group. Similarly, there were totally 15 subjects ie. 37.5% of the Group I 
who had a Salivary Glucose level of 1mg/dl out of which 5 were males and 
10 were females accounting for 31.3% and 41.7% respectively of the total 
number of males and females present in the group. There were 11 subjects 
ie. 27.5% of the Group I who had a Salivary Glucose level of 2mg/dl out of 
which 4 were males and 7 were females accounting for 25.0% and 29.2% 
respectively of the total number of males and females present in the group. 
There were 5 subjects ie. 12.5% of the Group I who had a Salivary Glucose 
level of 3mg/dl out of which 2 were males and 3 were females accounting 
for 12.5% and 12.5% respectively of the total number of males and females 
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present in this group. There were 2 subjects ie. 12.5% of the Group I who 
had a Salivary Glucose level of 4mg/dl out of which 2 were males and 0 
were females accounting for 12.5% and 0% respectively of the total number 
of males and females present in the group. There was 1 subject ie. 2.5% of 
the Group I who had a Salivary Glucose level of 5mg/dl out of which 1 was 
male and there were 0 females accounting for 6.3% and 0% respectively of 
the total number of males and females present in this group. There was 1 
subject ie. 2.5% of the Group I who had a Salivary Glucose level of 7mg/dl 
out of which there were 0 males and 1 female accounting for 0% and 4.2% 
respectively of the total number of males and females present in this group. 
Lastly, there was 1 subject ie. 2.5% of the Group I who had a Salivary 
Glucose level of 8mg/dl out of whom there were 0 males and 1 female 
accounting for 0% and 4.2% respectively of the total number of males and 
females present in this group. An insignificnat p value of >.005 was found. 
Table 8: Salivary Glucose level distribution according to Sex in Group 
II (Type 2 Diabetes Mellitus) 
This table shows the distribution of subjects based on Salivary 
Glucose levels and Sex in Group II. The Salivary Glucose levels varied 
from 1–5mg/dl in this group. Totally, there were 40 patients among the 
distribution of 16 males and 24 females. Out of which there were totally 9 
subjects ie. 22.5% of the Group II who had a Salivary Glucose level of 
1mg/dl out of which 3 were males and 6 were females accounting for 18.8% 
and 25.0% of the total number of males and females present in this group. 
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Similarly, there were totally 19 subjects ie. 47.5% of the Group II who had a 
Salivary Glucose level of 2mg/dl out of which 8 were males and 11 were 
females accounting for 50.0% and 45.8% respectively of the total number of 
males and females present in this group. There were 5 subjects ie. 12.5% of 
the Group II who had a Salivary Glucose level of 3mg/dl out of which there 
was 1 male and 4 females accounting for 6.3% and 16.7% respectively of 
the total number of males and females present in this group. There were 4 
subjects ie. 10.0% of the Group I who had a Salivary Glucose level of 
4mg/dl out of which 2 were males and 2 were females accounting for 12.5% 
and 8.3% respectively of the total number of males and females present in 
this group. Finally, there were 3 subjects ie. 7.5% of the Group II who had a 
Salivary Glucose level of 5mg/dl out of which 2 were males and 1 was a 
female accounting for 12.5% and 4.2% respectively of the total number of 
males and females present in this group. An insignificant p value of >.005 
was found. 
Table 9: Salivary Glucose distribution according to Age in Group I 
(Healthy Controls) 
This table shows the distribution of subjects based on Salivary 
Glucose levels and their Age in Group I. The Salivary Glucose levels varied 
from 0 – 8mg/dl in this group. Salivary Glucose level of 0mg/dl was found 
in totally 4 subjects comprising 10% of the total subjects out of whom there 
was 1 subject (25.0%) totally out of the Below 35yrs age group, 0 (0%) in 
the 36-45yrs age group, 2 (15.4%) in age group 46-55yrs and 1 (7.1%) age 
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group above 55yrs. Similarly, the Salivary Glucose level of 1mg/dl was 
found totally in 15 subjects comprising of 37.5% out of whom there were 3 
subjects (75.0%)totally who belonged to the below 35yrs age group, 4 
(44.4%) in 36-45yrs age group, 2 (15.4%) in 46 – 55yrs age group and 6 
(42.9%) in above 55yrs age group. Salivary Glucose level of 2mg/dl was 
found in 11 patients accounting for 27.5% of the entire  group totally out of 
which 0 (0%) subjects below 35yrs age group, 3 (33.3%) in 36-45yrs age 
group, 6 (46.2%) in 46 – 55yrs age group and 2 (14.3%) in above 55yrs age 
group.Salivary Glucose level of 3mg/dl was found totally in 5 subjects 
accounting for 12.5% of the entire group, out of which 0 (0%) subjects were 
below 35yrs age group, 1 (11.1%) in 36-45yrs age group, 0 (0%) in            
46–55yrs age group and 4 (28.6%) in above 55yrs age group.Salivary 
Glucose level of 4mg/dl was found to be present in totally 2 subjects 
accounting for 5.0% of the groups with 0 subjects below 35yrs age group, 0 
in 36-45yrs age group, 2 (15.4%) in 46–55yrs age group and 0 (0%) in 
above 55yrs age group. Salivary glucose level of 5mg/dl was found in only 
1 subject accounting for 2.5% of the population with 0 (0%) subject below 
35yrs age group, only 1 (11.1%) in 36-45yrs age group, 0 (0%) in              
46–55yrs age group and 0 (0%) in above 55yrs age group.Salivary Glucose 
level of 7mg/dl was found in only 1 subject accounting for 2.5% of the 
entire group with 0 (0%) subjects present in the below 35yrs age group, 0 
(0%) in 36-45yrs age group, 1 (7.7%) in 46 – 55yrs age group and 0 (0%) in 
the above 55yrs age group. Finally, Salivary Glucose level of 8mg/dl was 
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found in only 1 patient accounting for 2.5% of the entire group with 0 (0%) 
subjects below 35yrs age group, 0 (0%) in 36-45yrs age group, 0 (0%) in          
46–55yrs age group and 1 (7.1%) in above 55yrs age group. Hence, of the 
40 patients in this group, 4 (10.0%) were among the <35yrs age group, 9 
(22.5%) in the 36-45yrs age group, 13 (32.5%) in the 46-55yrs age group 
and finally 14 (35.0%) in the >55yrs age group. Insignificant p value of 
>.005 was found.   
Table 10:Salivary Glucose level distribution according to Age in Group 
II (Type II Diabetes Mellitus) 
This table shows the distribution of subjects based on Salivary 
Glucose levels and Age in Group II. The Salivary Glucose levels varied 
from 1 – 5mg/dl in this group. Salivary Glucose level of 1mg/dl was found 
in totally 9 (22.5%) subjects of the entire group among whom 0 (0%) 
subjects were there in the below 35yrs age group, 3 (33.3%) in the 36-45yrs 
age group, 3 (23.1%) in 46-55yrs age group and 3 (21.4%) in the age group 
above 55yrs. Similarly, the Salivary Glucose level of 2mg/dl was found in 
totally 19 (47.5%) patients in the entire group among whom 3 (75%)subjects 
were in the below 35yrs age group, 3 (33.3%) in 36-45yrs age group, 6 
(46.2%) in 46 – 55yrs age group and 7 (50%) in above 55yrs age group. 
Salivary Glucose level of 3mg/dl was found totally in 5 subjects accounting 
for 12.5% of the entire group out of which 0 (0%) subjects were present in 
the below 35yrs age group, 2 (22.2%) in 36-45yrs age group, 2 (15.4%) in 
46 – 55yrs age group and 1 (7.1%) in above 55yrs age group. Salivary 
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Glucose level of 4mg/dl was found in totally 4 subjects among accounting 
for 10.0% of the population among whom1 (25.0%) subject was in the 
below 35yrs age group, 0 (0%) in 36-45yrs age group, 1 (7.7%) in 46 – 
55yrs age group and 2 (14.3%) in above 55yrs age group. Salivary glucose 
level of 5mg/dl was found totally in 3 subjects accounting for 7.5% of the 
group with 0 (0%) subjects below 35yrs age group, 1 (11.1%) in 36-45yrs 
age group, 1 (7.7%) in 46 – 55yrs age group and lastly 1 (7.1%) in above 
55yrs age group.Hence, of the 40 patients in this group, 4 (10.0%) were 
among the <35yrs age group, 9 (22.5%) in the 36-45yrs age group, 13 
(32.5%) in the 46-55yrs age group and finally 14 (35.0%) in the >55yrs age 
group. The p value was found to be insignificant at >.005. 
Table 11: Fasting Blood Glucose distribution according to Sex in Group 
I (Healthy Controls) 
This table shows the distribution of Fasting blood glucose in males 
and females in Group I.The subjects among this group were Healthy Non 
Diabetic controls who had a Fasting Blood Glucose of <125mg/dl with a 
distribution of 16 males and 24 females. The Mean Fasting Blood Glucose 
was found to be 101.63mg/dl in males and 93.54mg/dl in females in this 
group.A significant p value < .005 was found.  
Table 12:  Fasting Blood Glucose level distribution according to sex in 
Group II (Type 2 Diabetes Mellitus) 
This table shows the distribution of Fasting Blood Glucose in males 
and females in Group II.The subjects among this group were known cases of 
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Type II Diabetes with a Fasting Blood Glucose of >125 mg/dl and 
comprised of 16 males and 24 females. The Mean Fasting Blood Glucose 
was found to be 208.13mg/dl in males and 197.67mg/dl in females in this 
group. A significant p value of <.005 was found. 
Table 13: Fasting Blood Glucose level distribution according to Age in 
Group I (Healthy Controls) 
This table shows the distribution of Fasting Blood Glucose <125 
mg/dl according to Age in Group I. There were 4 subjects present in the 
<35yrs age group, with a mean Fasting Blood glucose of 79mg/dl, 9 
subjects in the 36-45yrs age group with a mean Fasting Blood Glucose of 
100.22mg/dl, with another 13 patients in the age group between 46-55yrs 
with a mean of 94.08mg/dl and finally 14 patients in the age group above 
55yrs with a mean Fasting Blood Glucose of 102.00mg/dl. The mean 
Fasting Blood Glucose among the entire group was 96.78mg/dl. A 
significant p value of <.005 was found. 
Table 14: Fasting Blood Glucose level distribution according to Age in 
Group II (Type 2 Diabetes Mellitus) 
This table shows the distribution of Fasting Blood Glucose of 
>125mg/dl according to age in Group II.There were 4 subjects present in the 
<35yrs age group, with a Mean Fasting Blood Glucose of 179 mg/dl, 9 
subjects in the 36-45yrs age group with a mean of 236.67 mg/dl, with 
another 13 patients in the age group between 46-55yrs with a mean of 
208.92 mg/dl and finally 14 patients in the age group above 55yrs with a 
Results 
  
 
63 
 
Mean Fasting Blood Glucose of 179.43 mg/dl. The mean Fasting Glucose 
among this group was 201.85 mg/dl. A significant p value of <.005 was 
found.  
Table 15: Multiple comparisons between Age and Fasting Blood 
Glucose in Group I (Healthy Controls) 
This table shows the multiple significant comparisons that were 
found between Age and Fasting Blood Glucose values in Group I (Healthy 
Controls). On comparison of the subjects in the below 35yrs age group with 
the subjects in the 36-45yrs age group a mean difference of (-)20.72 was 
found and an insignificant p value of >.005. On comparison of the subjects 
in the below 35yrs age group with those in the 46-55yrs a mean difference 
of (-) 14.58 was found with an insignificant p value of >.005. The 
comparison of the subjects in the below 35yrs age group with the subjects in 
the above 55yrs age group a mean difference of (-)22.50 and a significant p 
value of < .005 was found. On comparing the subjects in the 36-45yrs age 
group with the subjects in the below 35yrs age group a mean difference of 
20.72 and an insignificant p value of >.005 was found. On comparing the 
36-45yrs age group with the subjects in the 46-55yrs a mean difference of 
6.15 and an insignificant p value of >.005. On comparing the subjects in the 
36-45yrs age group with those in the above 55yrs age group a mean 
difference of (-) 1.78 and an insignificant p value of >.005 was found. On 
comparing the subjects in the 46-55yrs age group with the subjects in the 
below 35yrs age group a mean difference of 14.58 and an insignificant p 
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value of >.005 was found. On comparing the subjects in the 46-55yrs age 
group with the subjects in the 36-45yrs age group a mean difference of (-) 
6.15 and an insignificant p value>.005 was found. On comparing the 
subjects in the 46-55yrs age group with the subjects in the above 55yrs a 
mean difference of (-)7.92 and an insignificant p value of >.005 was found. 
On comparing the subjects in the above 55yrs age group with the subjects in 
the below 35yrs a mean difference of 22.50 and a significant p value of        
< .005 was found. On comparing the subjects in the above 55yrs age group 
with the subjects in the 36-45yrs age group a mean difference of 1.78 and an 
insignificant p value of >.005 was found. And finally, on comparing the 
subjects in the above 55yrs age group with the subjects in the 46-55yrs a 
mean difference of 7.92 and an insignificant p value of >.005 was found. 
Table 16: Correlation between Fasting Blood Gluose and Salivary 
Glucose in Group I (Healthy Controls) 
This table shows the corelation between the Fasting Blood Glucose 
(<125 mg/dl) and the Salivary Glucose values in Group I (Healthy control). 
The Pearson Correlation was utilized. A p value in this group of 40 subjects 
was found to be >.005 which is insignificant. 
Table 17: Corelation between Fasting blood glucose and Salivary 
Glucose in Group II (Type 2 Diabetes Mellitus) 
This table shows the corelation between the Fasting Blood Glucose 
(>125 mg/dl) and the Salivary Glucose levels in Group II (Type 2 
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Diabetics). The Pearson Correlation was utilized. An insignificant p value of 
>.005 was found in this group of 40 subjects. 
Table 18: Correlation between Salivary and Fasting Blood Glucose 
levels in Group I and II. 
This table shows the correlation between the Salivary and Fasting 
Blood Glucose levels among the Healthy controls and the Type 2 Diabetes 
Mellitus subjects. The Pearson Correlation was utilized. An insignifiant           
p value of >.005 was found in the total sample of 80 subjects. 
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Table 1: Sex Wise Distribution of Subjects in Group I 
  (Healthy Controls)  
 
  
 
VALID 
 
FREQUENCY 
 
PERCENT (%) 
 
MALE 
 
16 40.0% 
 
FEMALE 
 
24 60.0% 
 
TOTAL 
 
40 100.0% 
 
p value < .005 (Significant) 
 
Table 2: Sex Wise Distribution of Subjects in Group II  
(Type 2 Diabetes Mellitus) 
 
p value < .005 (Significant) 
 
 
VALID 
 
FREQUENCY 
 
PERCENT 
(%) 
 
MALE 
 
16 40.0% 
 
FEMALE 
 
24 60.0% 
 
TOTAL 
 
40 100.0% 
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Table 3: Age Wise Distribution of Subjects in Group I  
(Healthy Controls) 
 
 
 
p value < .005 (Significant) 
 
 
Table 4: Age Wise Distribution of Subjects in Group II  
(Type 2 Diabetes Mellitus) 
 
 
VALID 
 
 
BELOW 
35 yrs 
 
36-45 
yrs 
 
46-55 
yrs 
 
ABOVE 
55 yrs 
 
TOTAL 
 
FREQUENCY 
 
 
4 
 
9 
 
13 
 
14 
 
40 
 
PERCENT (%) 
 
 
10.0% 
 
22.5% 
 
32.5% 
 
35.0% 
 
100.0% 
 
 
p value < .005 (Significant) 
 
 
 
 
VALID 
 
 
BELOW 
35yrs 
 
36-45 
yrs 
 
46-55 
yrs 
 
ABOVE 
55 yrs 
 
TOTAL 
 
FREQUENCY 
 
 
4 
 
 
9 
 
 
13 
 
14 
 
40 
 
PERCENT (%) 
 
10.0% 22.5% 
 
32.5% 
 
35.0% 
 
100.0% 
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Table 5: Age and Sex Wise Distribution of Subjects in Group I  
(Healthy Controls) 
AGE IN YEARS 
SEX 
TOTAL 
MALE FEMALE 
BELOW 35yrs 
 
1 3 4 
6.3% 12.5% 10.0% 
36-45yrs 
 
5 4 9 
31.3% 16.7% 22.5% 
46-55yrs 
 
5 8 13 
31.3% 33.3% 32.5% 
ABOVE 55yrs 
 
5 9 14 
31.3% 37.5% 35.0% 
TOTAL 16 24 40 
40.0% 60.0% 100.0% 
 
 
Age range – 28 -75 yrs Mean age – 50.97yrs   
p value <.005 (Significant)  
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Table 6: Age and Sex Wise Distribution of Subjects in Group II  
(Type 2 Diabetes Mellitus) 
 
AGE IN YEARS 
SEX 
TOTAL 
MALE FEMALE 
BELOW 35yrs 1 3 4 
 6.3% 12.5% 10.0% 
36-45yrs 5 4 9 
 31.3% 16.7% 22.5% 
46-55yrs 5 8 13 
 31.3% 33.3% 32.5% 
ABOVE 55yrs 5 9 14 
 31.3% 37.5% 35.0% 
TOTAL 
 
16 24 40 
40.0% 60.0% 100.0% 
 
Age range – 28 – 75 yrs Mean age – 50.97 yrs  
p value <.005 (Significant) 
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Table 7: Salivary Glucose Distribution according to Sex in Group I 
(Healthy Controls) 
Salivary Glucose 
mg/dl 
Sex 
Total 
Male Female 
0 mg/dl 
 
2 2 4 
12.5% 8.3% 10.0% 
1 mg/dl 
 
5 10 15 
31.3% 41.7% 37.5% 
2 mg/dl 
 
4 7 11 
25.0% 29.2% 27.5% 
3 mg/dl 
 
2 3 5 
12.5% 12.5% 12.5% 
4 mg/dl 
 
2 0 2 
12.5% .0% 5.0% 
5 mg/dl 
 
1 0 1 
6.3% .0% 2.5% 
7 mg/dl 
 
0 1 1 
.0% 4.2% 2.5% 
8 mg/dl 
 
0 1 1 
.0% 4.2% 2.5% 
Total 
 
16 24 40 
40.0% 60.0% 100.0% 
 
p value > .005 (Insignificant)  
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Table 8: Salivary Glucose Distribution according to Sex in Group II 
(Type 2 Diabetes Mellitus) 
Salivary Glucose 
mg/dl 
Sex 
Total 
Male Female 
1 mg/dl 
 
3 6 9 
18.8% 25.0% 22.5% 
2 mg/dl 
 
8 11 19 
50.0% 45.8% 47.5% 
3 mg/dl 
 
1 4 5 
6.3% 16.7% 12.5% 
4 mg/dl 
 
2 2 4 
12.5% 8.3% 10.0% 
5 mg/dl 
 
2 1 3 
12.5% 4.2% 7.5% 
Total 
 
16 24 40 
40.0% 60.0% 100.0% 
 
p value >.005 (Insignificant) 
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Table 9: Salivary Glucose Distribution according to Age in Group I 
(Healthy Controls) 
Salivary 
Glucose 
mg/dl 
Age in years 
Total Below 
35yrs 
36-45 yrs 46-55 yrs 
Above 
55yrs 
0 mg/dl 
1 
 
0 
 
2 
 
1 
 
4 
 
25.0% 
 
.0% 
 
15.4% 
 
7.1% 
 
10.0% 
 
1 mg/dl 
 
3 
 
4 
 
2 
 
6 
 
15 
 
75.0% 
 
44.4% 
 
15.4% 
 
42.9% 
 
37.5% 
 
2 mg/dl 
 
 
0 
 
3 
 
6 
 
2 
 
11 
 
.0% 
 
33.3% 
 
46.2% 
 
14.3% 
 
27.5% 
 
3 mg/dl 
 
 
0 
 
1 
 
0 
 
4 
 
5 
 
.0% 
 
11.1% 
 
.0% 
 
28.6% 
 
12.5% 
 
4 mg/dl 
 
 
0 
 
0 
 
2 
 
0 
 
2 
 
.0% 
 
.0% 
 
15.4% 
 
.0% 
 
5.0% 
 
5 mg/dl 
 
 
0 
 
1 
 
0 
 
0 
 
1 
 
.0% 
 
11.1% 
 
.0% 
 
.0% 
 
2.5% 
 
7 mg/dl 
 
 
0 
 
0 
 
1 
 
0 
 
1 
 
.0% 
 
.0% 
 
7.7% 
 
.0% 
 
2.5% 
 
8 mg/dl 
 
 
0 
 
0 
 
0 
 
1 
 
1 
 
.0% 
 
.0% 
 
.0% 
 
7.1% 
 
2.5% 
 
Total 
4 
 
9 
 
13 
 
14 
 
40 
 
10.0% 
 
22.5% 
 
32.5% 
 
35.0% 
 
100.0% 
 
 
p value > .005 (Insignificant) 
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Table 10: Salivary Glucose distribution according to Age in Group II 
(Type 2 Diabetes Mellitus) 
Salivary 
Glucose 
mg/dl 
 
AGE IN YEARS 
TOTAL 
Below 
35yrs 36-45 yrs 46-55 yrs 
Above 
55yrs 
1 mg/dl 0 
 
3 
 
3 
 
3 
 
9 
 
 .0% 
 
33.3% 
 
23.1% 
 
21.4% 
 
22.5% 
 
2 mg/dl 3 
 
3 
 
6 
 
7 
 
19 
 
 75.0% 
 
33.3% 
 
46.2% 
 
50.0% 
 
47.5% 
 
3 mg/dl 0 
 
2 
 
2 
 
1 
 
5 
 
 .0% 
 
22.2% 
 
15.4% 
 
7.1% 
 
12.5% 
 
4 mg/dl 1 
 
0 
 
1 
 
2 
 
4 
 
 25.0% 
 
.0% 
 
7.7% 
 
14.3% 
 
10.0% 
 
5 mg/dl 0 
 
1 
 
1 
 
1 
 
3 
 
 .0% 
 
11.1% 
 
7.7% 
 
7.1% 
 
7.5% 
 
Total 
 
4 
 
9 
 
13 
 
14 
 
40 
 
10.0% 
 
22.5% 
 
32.5% 
 
35.0% 
 
100.0% 
 
 
p value > .005 (Insignificant) 
 
 
 
Tables & Graphs 
 
74 
 
Table 11: Fasting Serum Glucose distribution according to Sex in 
Group I (Healthy Controls) 
 
 
Fasting Blood 
Sugar mg/dl 
 
Sex 
 
 
N 
 
 
Mean 
 
 
<125 mg/dl  
Male 
 
16 101.63 
<125 mg/dl  
Female 
 
24 93.54 
 
p value <.005 (Significant) 
 
Table 12: Fasting Serum Glucose distribution according to Sex in 
Group II (Type 2 Diabetes Mellitus) 
 
 
Fasting Blood 
Sugar mg/dl 
 
 
Sex 
 
 
N 
 
 
Mean 
 
 
>125 mg/dl  
Male 
 
16 208.13 
>125 mg/dl  
Female 
 
24 197.67 
    
    p value <.005 (Significant) 
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Table 13: Fasting Blood Glucose (<125 Mg/dl) distribution according to 
Age in Group I (Healthy Controls) 
 
 
AGE 
 
 
BELOW 
35yrs 
 
36-45 yrs 46-55 yrs 
 
ABOVE 
55yrs 
 
TOTAL 
 
N 
 
4 9 13 14 40 
 
MEAN 
(mg/dl) 
79.00 100.22 94.08 102.00 96.78 
 
 
p value <.005 (Significant) 
 
Table 14: Fasting Serum Glucose distribution according to Age in 
Group II (Type 2 Diabetes Mellitus) 
 
AGE 
 
BELOW 
35yrs 
36-45 yrs 46-55 yrs 
 
ABOVE 
55yrs 
 
TOTAL 
N 
 
4 9 13 14 40 
MEAN 
(mg/dl) 
179.00 236.67 
 
208.92 
 
 
179.43 
 
 
201.85 
 
 
 
p value<.005 (Significant) 
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Table 15: Multiple Comparisons between Age and Fasting Blood 
Glucose in Group I (Healthy Controls) 
(I) Age in years 
 
 
(J) Age in years 
 
 
Mean 
Difference (I-J) 
 
 
Sig. 
 
 
 
Below 35yrs 
 
 
36-45 yrs 
-20.72(*) .018 
 
 
46-55 yrs 
 
-14.58 .117 
 
 
Above 55yrs 
 
-22.50(*) .005 
 
36-45 yrs 
 
 
Below 35yrs 
20.72(*) .018 
 
 
46-55 yrs 
 
6.15 .582 
 
 
Above 55 yrs 
 
-1.78 .982 
 
46-55 yrs 
 
 
Below 35yrs 
14.58 .117 
 
 
36-45 yrs 
 
-6.15 .582 
 
 
Above 55yrs 
 
-7.92 .265 
 
Above 55 yrs 
 
 
Below 35yrs 
22.50(*) .005 
 
 
36-45 yrs 
 
1.78 .982 
 
 
46-55 yrs 
 
7.92 .265 
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Table 16: Correlation between Fasting Blood Glucose and Salivary 
Glucose in Group I (Healthy Controls) 
 
  
 
 
Fasting Blood Sugar 
mg/dl 
Salivary 
Glucose mg/dl 
 
Pearson Correlation 
 
1 0.083 
 
Sig. (2-tailed) 
 
- 0.610 
 
N 
 
40 40 
 
Pearson Correlation 
 
0.083 1 
 
Sig. (2-tailed) 
 
0.610 - 
 
N 
 
40 40 
 
p value >.005 (Insignificant) 
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Table 17: Correlation between Fasting Blood Glucose and Salivary 
Glucose in Group II (Type 2 Diabetes Mellitus) 
 
 
 
 
Fasting Blood Sugar 
mg/dl 
Salivary 
Glucose mg/dl 
 
Pearson Correlation 
 
1 0.118 
 
Sig. (2-tailed) 
 
- 0.468 
 
N 
 
40 40 
 
Pearson Correlation 
 
0.118 1 
 
Sig. (2-tailed) 
 
0.468 - 
 
N 
 
40 40 
 
p value >.005 (Insignificant) 
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Table 18: Correlation between Salivary and Serum Glucose levels 
 
 
 
 
Fasting Blood Sugar 
mg/dl 
Salivary 
Glucose mg/dl 
 
Pearson Correlation 
 
1 0.136 
 
Sig. (2-tailed) 
 
- 0.228 
 
N 
 
80 80 
 
Pearson Correlation 
 
0.136 1 
 
Sig. (2-tailed) 
 
0.228 - 
 
N 
 
80 80 
 
 
p value > .005 (Insignificant) 
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Graph 1: Sex Wise Distribution of Subjects in Group I  
(Healthy Controls) 
 
 
 
 
 
 
 
 
 
 
 
Graph 2: Sex Wise Distribution of Subjects in Group II 
(Type 2 Diabetes Mellitus) 
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Graph 3: Age Wise Distribution of Subjects in Group I  
(Healthy Controls) 
 
 
 
 
 
 
 
 
 
Graph 4: Age Wise Distribution of Subjects in Group II  
(Type 2 Diabetes Mellitu) 
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Graph 5: Age and Sex Wise Distribution of Subjects in Group I 
 (Healthy Controls) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 6: Age and Sex Wise Distribution of Subjects in Group II 
(Type 2 Diabetes Mellitus) 
 
 
 
 
 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
Below 35 36-45 46-55 Above 55
25.00% 
55.60% 
38.50% 
35.70% 
75.00% 
44.40% 
61.50% 
64.30% 
Male
Female
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
Below 35 36-45 46-55 Above 55
25.0% 
55.6% 
38.5% 
35.7% 
75.0% 
44.4% 
61.5% 
64.3% 
Male
Female
Tables & Graphs 
 
 
83 
 
Graph 7: Salivary Glucose Distribution According to Sex in Group I 
(Healthy Controls) 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 8: Salivary Glucose Distribution According to Sex in Group II 
(Type 2 Diabetes Mellitus) 
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Graph 9: Salivary Glucose Distribution According to Age in Group I 
(Healthy Controls) 
 
 
 
 
 
 
 
 
 
 
Graph 10: Salivary Glucose Distribution According to Age in Group II 
 (Type 2 Diabetes Mellitus) 
 
 
 
 
 
 
 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Below 35 36-45 46-55 Above 55
25.0% 
0.0% 
50.0% 
25.0% 
20.0% 
26.7% 
13.3% 
40.0% 
0.0% 
2 .3% 
54.5% 
18.2% 
.0% 
20.0% 
0.0% 
80.0% 
.0% 0.0% 
100.0% 
0.0% .0% 
100.0% 
0.0% .0% .0% 0.0% 
100.0% 
.0% .0% .0% 0.0% 
100.0% 
Series2
Series3
Series1
Series4
Series5
Series6
Series7
Series8
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
Below 35 36-45 46-55 Above 55
0.0% 
33.3% 33.3% 33.3% 
15.8% 15.8% 
31.6% 
36.8% 
0.0% 
40.0% 40.0% 
20.0% 
25.0% 
0.0% 
25.0% 
50.0% 
0.0% 
33.3% 33.3% 33.3% 
Series2
Series3
Series1
Series4
Series5
Tables & Graphs 
 
 
85 
 
Graph 11: Fasting Serum Glucose Distribution According to Sex in 
Group I (Healthy Controls) 
 
 
 
 
 
 
 
 
 
 
 
Graph 12: Fasting Serum Glucose Distribution According to Sex in 
Group II (Type 2 Diabetes Mellitus) 
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Graph 13: Fasting Blood Glucose Distribution According to Age in  
Group I (Healthy Controls) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 14: Fasting Serum Glucose Distribution According to Age in 
Group II (Type 2 Diabetes Mellitus) 
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Graph 15: Multiple Comparison Between Age and Fasting Blood Glucose 
in Group I (Healthy Controls) 
 
 
 
 
 
 
 
 
 
 
 
Graph 16: Correlation between Fasting Blood Glucose and Salivary 
Glucose in Group I (Healthy Controls) 
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Graph 17: Correlation between Fasting Blood Glucose and Salivary 
Glucose in Group II (Type 2 DiabetesMellitus) 
 
 
 
 
 
 
 
 
 
 
Graph 18: Correlation between Salivary and Serum Glucose levels 
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Diabetes Mellitus is a complex group of syndromes that have in 
common, a disturbance in the body’s use of glucose, resulting in elevated 
blood glucose levels. Blood glucose monitoring by the patient and the 
physician is an important aspect in the control of the devastating 
complications due to the disease. With ever improving advances in 
diagnostic pathology, the race for the next generation of bloodless, painless 
and accurate glucose instruments has begun. Most commonly used 
laboratory diagnostic procedures involve the analysis of blood, but other 
biological fluids are also being utilized for the diagnosis of other diseases 
and of these, saliva offers distinctive advantages.
74 
Knowledge of the components of saliva is important because they 
may indicate oral or systemic alterations, and it is also important because 
saliva may be a substitute for blood in lab tests for the diagnosis of illnesses. 
Several studies evaluate the concentration of glucose in the saliva of 
diabetic patients. Though differences in the output and composition of saliva 
from Diabetic and Non Diabetic subjects have been observed in a number of 
studies, many of these findings have been contradictory.
74 
Saliva offers some distinctive advantage as it can be collected non-
invasively and by individuals with limited training However, studies 
pertaining to the use of saliva as a non invasive tool in monitoring blood 
glucose levels in diabetic patients have been done predominantly in the 
Western population.
9,10
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 The aim of the present study was to compare the Salivary Glucose 
and Serum Glucose concentration in Non-Insulin dependent Diabetes 
Mellitus patients and the Non Diabetic Healthy individuals in a Chennai 
based population. 
The study was conducted between March 2010 and April 2011 at 
Voluntary Health Services, Adyar, Chennai.   
A case control study was conducted in which 80 patients were 
included. The study subjects were categorized into two groups out of which 
40 were suffering from Type 2 Diabetes Mellitus and the other 40 were    
Non Diabetic Healthy individuals. 
Participants with infectious diseases during one month before saliva 
sampling, active dental abscesses, and collagen vascular diseases were 
excluded from the study. 
In India, the mean age of onset of Type 2 Diabetes in men is 44.0 ± 
8.3yrs and in women the mean age is 42.9 ± 10.0yrs with a male 
predominance and a Male to Female ratio of 2:1. In our study, among the 80 
subjects, 32 (40%) were males and 48 (60%) were females. The minimum 
age of the study subjects was 28yrs and the maximum age was 75yrs. The 
mean age among both men and women was found to be 50.97yrs, with a 
female predominance. This is in accordance with Sreedevi et al
71
 whose 
patients had a mean age of 49.7yrs, though with a male predominance. The 
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gender variation could be attributed to the regional difference and the 
selection criteria in this study. Cedric et al
76
 found a predominance of 
females in their study too with an age range of 56 ± 3 in males and 55 ± 2 in 
females. While Michael W.J. Dodds
79
 saw a male predominance in their 
study though the mean age was similar to our study at 50.5 yrs. Similarly 
even Veena et al
74
 found that the mean age of the diabetics was 51.65 ± 
10.22 with a male predominance. 
  The current study involved subjects with Type 2 Diabetes Mellitus 
and a Healthy control group. The control group had a mean Fasting serum 
glucose level of 101.63mg/dl in males and 93.54mg/dl in females when 
compared to the Diabetic group who were found to have a mean Fasting 
serum glucose level of 208.13mg/dl in males and 197.67mg/dl in females 
which was significantly higher with a p value <.005. This is in accordance 
with Hegde et al
73
 who found that the control group had a Fasting serum 
glucose level of 99.71 ± 6.92 while the Diabetic group had a value of 144.31 
± 53.55 with a significant p value <.005 when compared to the Healthy 
control group. Sreedevi et al
71
 found that the Fasting serum glucose had a 
mean of 105.7 ± 22.3mg% in the control group while it was significantly 
higher with a value of 309.5 ± 68.2mg% in the Diabetics and a p value 
<.005. Veena et al
74
 found that the Fasting serum glucose level among the 
control group was 95.58 ± 12.01mg/dl and that among the Diabetics ranged 
between 180-200mg/dl with a p value of <.005. Nakamoto et al
83
 also 
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found the Fasting serum glucose level to be 115.7 ± 35.7mg/dl in the 
Diabetic group which was significantly higher than the control group with a 
p value of <.005. 
Despite the significant differences in Fasting serum glucose levels, 
the Salivary glucose (SG) levels did not differ and were comparable 
between the two groups in our study. In this study, the average salivary 
glucose level found among the Healthy male and female individuals was 
2mg/dl, while in the Diabetics it was found to be 2.5mg/dl in males and 2.2 
mg/dl in females respectively with an insignificant p value >.005. While in a 
study done by Maria-Sueli-Marques Soares et al
84
 to evaluate the salivary 
glucose level in unstimulated saliva of healthy individuals, the average 
Salivary Glucose level was found to be at a higher level compared to our 
study at 5.94mg/dl. An explanation for these differences may be the choice 
of certain study designs, as well as the diversity of the methods and criteria 
for selecting the samples. In this study, the measurements were recorded 
with the whole unstimulated flow rate. We have observed in our study that 
the modifications of the levels of capillary glycemia are not reflected in the 
saliva, which is in accordance with Maria-Sueli-Marques Soares et al
84
. 
On the other hand, Sreedevi et al
71
 found the Salivary glucose level to range 
between 0.7 to 1.3mg% in the control group while in the Diabetic group it 
ranged between 1.5 to 8.0mg% with a significant p value <.005. 
Sashikumar et al
72
 found the Salivary glucose levels to range between         
1.5–25.6mg/dl in the Diabetic group while it was 0.2–7.7mg/dl in the 
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Control group with an insignificant p value >.005. The levels of Salivary 
glucose in the control group is similar to the one found in our study and this 
could be attributed to the fact that this study was also done in a chennai 
based population. Veena et al
74
 found in their study that the Salivary 
glucose level ranged between 4.1 to 13.3mg/dl in the Control subjects while 
in the Diabetic group it was found to be 4.1 to 26.6mg/dl with a significant          
p value <.005. Sathya Priya et al
75
 found that the Salivary glucose level 
ranged between 5.91–8.15mg/dl in the Control group while in the Diabetic 
group it ranged between 7.64-16.20mg/dl with a significant p value <.005.     
With an increase in age, there was found to be a significant increase 
in the Fasting blood glucose levels in the control group, which is in 
accordance with Arati S. Panchbai et al
87 
who found a significant p value 
<.005, signifying that with an increase in age there is a greater 
predisposition to diabetes.    
An insignificant correlation with a p value >.005 was found between 
the Fasting blood glucose and the Salivary glucose levels in the Healthy 
control group. This is in accordance with Hegde et al
73
 who found an 
insignificant p value >.005 and Sashikumar et al
72 
who also found an 
insignificant p value >.005 in their study. But not in accordance with Cedric 
et al
76
 who found a siginificant correlation with a p value <.005 between the 
Fasting blood glucose and Salivary glucose levels in their healthy group. 
Veena v. Naik et al
74
 also in their study found a positive correlation 
between the Fasting blood glucose and the Salivary glucose with a p value 
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<.005. This variation in the study results could be attributed to the fact that 
this study unlike others included subjects from a Chennai based population 
who are known to have a carbohydrate rich dietary pattern.  
Similarly an insignificant correlation was found between the Fasting 
blood glucose levels and the Salivary glucose levels in the Diabetic group 
with a p value >.005 which again is in accordance with Hegde et al
73
 who 
also found no relation between the Fasting blood glucose and the Salivary 
glucose levels in their Diabetic subjects with a p value of >.005 but not in 
accordance with Cedric et al
76
 who found a significant correlation between 
their Fasting blood glucose and Salivary glucose levels with a p value 
<.005. Veena v. Naik et al
74
 in their study also had a highly significant             
p value < .005. Similarly Aydin et al
81
 also found a significant correlation 
between the Fasting blood glucose and the Salivary glucose values with a          
p value <.005. Sreedevi et al
71
, Nakamoto et al
83
, Amer et al
80
, 
Sashikumar et al
72
 and Sathya Priya et al
75
 also found a significant 
correlation between the Fasting blood glucose and the Salivary glucose with 
a p value <.005.   
In our study, an insignificant correlation was found between the 
Salivary glucose and the Fasting blood glucose levels in both Healthy and 
Diabetic group with a p value >.005. This is in accordance with Hegde et 
al
73
 who concluded that the Diabetic group had significantly high Fasting 
serum glucose as compared to controls though despite these significant 
differences in Fasting serum glucose levels, the Salivary glucose levels did 
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not differ and were comparable between the two groups with an 
insignificant p value >.005. Our study is not in accordance with Cedric et 
al
76
 who found that the glucose concentration in saliva is higher in Diabetic 
patients than in control subjects with a p value <.005. Neither is it, in 
accordance with Arati S. Panchbhai
87
 who concluded that the Mean 
salivary glucose levels were clearly higher in Diabetics when compared to 
the Healthy Non Diabetics with a significant p value <.005. Similarly, 
Veena v. Naik et al
74
 also concluded that a positive correlation was found 
between Blood glucose and Salivary glucose levels in both the Diabetics 
and the controls with a p value <.005 and that saliva could be used as an 
adjunct diagnostic tool in Diabetes Mellitus. Sreedevi et al
71
 also concluded 
that as there was a significant correlation between Salivary glucose and 
Serum glucose with a highly significant p value <.005 and that Saliva does 
hold the potential of being a marker in diabetes. Amer et al
80
 also found a 
significant p value of <.005 in their study and that the Salivary glucose 
concentrations seem to correlate with the Serum glucose concentration in 
the patients of Diabetes Mellitus. And finally, Sashikumar et al
72
 found 
that Salivary glucose levels were significantly higher in Diabetics than              
Non Diabetics and that there was a significant positive correlation between 
Salivary and serum glucose levels with a p value <.005. The variation in the 
results could be attributed to a smaller sample size in our study as well as a 
variation in the study design, sample population in terms of female 
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predominance as well as regional variation due to a purely Chennai based 
population. 
These findings confirm the poor link between glycaemia and glucose 
concentration or excretion in saliva, atleast on an individual basis. 
Nevertheless, the present study may well set the scene for further 
investigations on the regulation of glucose output from salivary glands, as 
well as on the potentially unfavorable effect of a high glucose salivary 
concentration on selected variables of oral health status in diabetic patients. 
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The present study titled “Comparison of Salivary Glucose and 
Serum Glucose concentration in Non-Insulin dependent Diabetes Mellitus 
patients” was conducted between March 2010 and April 2011 in the Out 
Patient Department of Voluntary Health Services, Adyar, Chennai to 
estimate the Salivary Glucose and Serum Glucose concentration in               
Non-Insulin dependent Diabeties Mellitus patients, to estimate the Salivary 
Glucose and Serum Glucose concentration in Healthy control group and 
finally to correlate these Salivary Glucose and Serum Glucose 
concentrations in Non-Insulin Dependent Diabetes Mellitus patients and 
healthy controls.  
The study group comprised of a total number of 80 patients. Out of 
the 80 patients, 40 were Healthy controls and the other 40 were suffering 
from Type 2 Diabetes Mellitus. Informed consent was taken from all 
subjects before including them in the study. Participants with infectious 
diseases during one month before saliva sampling, active dental abcesses, 
and collagen vascular diseases were excluded from the study.  
The experimental subjects were made to sit comfortably on a chair. 
Relevant demographic data was collected. An Intra Oral examination was 
carried out. Whole un-stimulated saliva was collected as well as the blood 
sample was collected. Saliva and blood samples were collected in sterile test 
tubes, immediately transferred aseptically to sterile tubes and frozen on dry 
ice and alcohol. The samples were stored in styroform boxes containing dry 
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ice and carried to a freezer where they are left until time of assessment of 
the Salivary glucose and Serum glucose. 
The study documents the following data: 
 Among the 80 subjects 48 (60%) were females and 32 (40%) 
were males. 
 The minimum age among the subjects was 28yrs and 
maximum was 75yrs with a mean of 50.97 yrs. 
 Among the 40 subjects in the Control group there was 1 
male and 3 females in the below 35yrs category, 5 males and 
4 females in the 36-45yrs category, 5 males and 8 females in 
the 46-55yrs category and finally 5 males and 9 females in 
the above 55yrs category.     
 As this was an age and sex matched study, among 40 
subjects in the Diabetic group there was 1 male and 3 
females in the below 35yrs category, 5 males and 4 females 
in the 36-45yrs category, 5 males and 8 females in the         
46-55yrs category and finally 5 males and 9 females in the 
above 55yrs category.     
 The distribution of Salivary glucose among the 40 subjects 
in the Healthy controls ranged from 0mg/dl to 8mg/dl. 
 Similarly, the Salivary glucose level distribution among the 
diabetics varied from 0mg/dl to 8mg/dl. 
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 The Mean fasting blood glucose among the healthy controls 
was 101.63mg/dl for males and 93.54mg/dl for females. 
 The Mean fasting blood glucose among the diabetics was 
208.13mg/dl for males and 197.67mg/dl for females.  
 A significant correlation was found between Age and 
Fasting blood glucose among the Healthy controls. 
 An insignificant correlation was found between the Salivary 
glucose and Fasting serum glucose level in the Healthy 
controls. 
 An insignificant correlation was found between the Salivary 
glucose and Fasting serum glucose levels in the Diabetic 
group. 
 Finally, an insignificant correlation was found between the 
Salivary glucose and Serum glucose. 
To conclude, Salivary glucose concentrations showed no difference 
between the Type 2 Diabetic and the Control group. This implies that the 
association of high Fasting serum glucose with high Salivary Glucose levels 
is an infrequent observation which may be affected by metabolic control of 
the disease. 
A large number of studies have been done in an attempt to check for 
the efficacy of Saliva as a diagnostic tool in Diabetes Mellitus. 
Unfortunately, there are no conclusive results. While the results of some 
studies give a go ahead to the usage of saliva as a diagnostic tool there are 
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others which disapprove of it. The need of the hour is larger studies that 
need to be performed in various parts of the world among different 
populations with different dietary patterns before a conclusive result is 
achieved.  
Hence, the usage of salivary glucose as the only tool for evaluating 
glycemic status is debatable. Studies to compare long term indicators of 
glycemic status like HbA
1
C, fructosamine levels with salivary glucose / 
glycated proteins should be under-taken with a larger sample size as well as 
keeping the importance of regional variations in mind. 
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RAGAS DENTAL COLLEGE AND HOSPITAL 
2/102 East Coast Road, Uthandi, Chennai – 600019 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
 
CASE SHEET PROFORMA 
A. GENERAL INFORMATION 
S.No:   O.P.No:  Date: 
 
1. Name: 
2. Age: 
3. Sex:    1. Male :  2. Female: 
4. Occupation: 
a. Unemployed 
b. Unskilled 
c. Skilled 
d. Professional 
e. Administration 
f. Trade/Business 
g. Student 
5. Address: 
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6. Income; 
a. <Rs. 1,000/month b. >1,000-5,000/month              
c.    >5,000/month 
B. History: 
 
1. History relating to Diabetes Mellitus 
a. Age at diagnosis of  Diabetes Mellitus 
b. Onset and duration of  Diabetes 
c. Family history of  Diabetes Mellitus 
2. Presence of  any other systemic disease 
a. Present  b. Absent 
If yes, specify 
3. History of medication; 
a. Yes   b. No 
If yes, specify Duration  Name of medicine  
 
INVESTIGATION 
1. Random Blood Sugar 
2. Salivary glucose estimation 
3. Fasting blood sugar 
4. Post Prandial  
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CONSENT LETTER 
I ________________________________  the undersigned hereby give my 
consent for the performance of the diagnostic test on myself “to evaluate the 
Serum and Salivary Glucose test” conducted by Dr. Ruchi Gera under the able 
guidance of Dr. S. Shanmugam, M.D.S., HOD Department of Oral Medicine, 
Diagnosis and Radiology at the Ragas Dental College and Hospital, Chennai. 
I have been informed and explained the status of my disorder, evaluation 
procedure, risk involved and likelihood of success. I also understand and accept 
this as a part of the study protocol, thereby voluntarily, unconditionally, freely give 
my consent without any pressure or fear in mentally sound and conscious state to 
participate in the study. 
Witness/Representative    Patient’s Signature 
(if any)       Date: 
åŠ¹î™ ð®õ‹ 
------------------------------------------------------ vd;fpd;w ehd;/ brd;id/ uhfh!; 
gy;kUj;Jtf; fy;Y}hp kw;Wk; kUj;Jtkidapy; tha; kUj;Jtk; kw;Wk; 
CLfjph; Jiwapd; nguhrphpah; kU. S. rz;Kfk; mth;fspd; nkw;ghh;itapy;/ 
KJepiy (M.D.S) gl;lg;gog;g[ gapYk; jpU. Ur;rp nfuh mth;fs; 
nkw;bfhs;Sk;/ “ePh;mHpt[ nehapy; ,uj;jk; kw;Wk; ckpH;ePhpy; cs;s 
rh;f;fiuapd; msit fz;lwpjy;” vd;fpd;w Ma;t[f;F vd; rk;kjj;ij 
bjhptpf;fpnwd;. nkYk;/ ,e;j Ma;tpd;/ tpist[fs; gw;wp mwpe;J ,e;j 
ghpnrhjidf;F ehd; ve;jtpj mr;rKkpd;wp jd;dpr;irahft[k;/ bjspthd 
KG kdJld; vd;Dila ghpg{ud rk;kjj;jpid mspf;fpnwd;. 
         
  ,g;gof;F 
rhl;rpahsh;fs;  
 
Date :  
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GROUP I 
S. No Name Age Sex 
Fasting 
Blood Sugar 
mg/dl 
Salivary 
Glucose mg/dl 
1 Manomani 54 M 93 4 
2 Neela 60 F 89 3 
3 Suresh 35 M 89 1 
4 Thondiammal 50 F 98 2 
5 Devendran 47 M 83 1 
6 Kamalavani 64 F 96 8 
7 Mani 53 M 99 4 
8 Shanti 48 F 100 7 
9 Venkatraman 40 M 100 5 
10 Vatsala 46 F 82 2 
11 Adilakshmi 64 F 103 1 
12 Srinivasan 48 M 107 2 
13 Vardhraj 40 M 92 2 
14 Lilly 60 F 97 1 
15 Tamil Arasi 28 F 84 1 
16 Thayar 40 F 98 3 
17 C.Arjuna 56 M 124 0 
18 Mangalakshmi 61 F 101 1 
19 M. Shanti 49 F 99 0 
20 Mahalingam 55 M 106 0 
21 Kamala 60 F 90 2 
22 Manavalan 65 M 107 3 
23 Vadivel 65 M 119 1 
24 P.Saroja 40 F 102 1 
25 Selvanayagi 68 F 105 2 
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26 Jahida 40 F 107 1 
27 Narayanaswamy 75 M 75 1 
28 Mayappan 66 M 110 3 
29 Anusuya 59 F 117 3 
30 Sundari 54 F 86 2 
31 S.Maheshwari 55 F 88 2 
32 Deepa C. 30 F 75 1 
33 Thondiammal C. 54 F 87 2 
34 Manjula Bai 57 F 95 1 
35 Madhusadan Rao 41 M 123 2 
36 Maniya 50 F 95 1 
37 Padma 40 F 81 1 
38 Chinni 30 F 70 0 
39 Srinivasan  43 M 107 1 
40 Vardhraj 37 M 92 2 
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Group II 
S. No Name Age Sex 
Fasting Blood 
Sugar mg/dl 
Salivary 
Glucose 
mg/dl 
1 Hemavathy 28 F 140 2 
2 Perumal 65 M 146 2 
3 P. Selvam 40 M 320 5 
4 Shiva 35 M 220 2 
5 J.Shanti 64 F 132 5 
6 Jaya 60 F 240 2 
7 Ranganayaki 50 F 195 2 
8 Perumal 65 M 146 1 
9 Selvi J. 40 F 240 3 
10 Shanti R 61 F 169 2 
11 Chellapan 48 M 171 2 
12 Rajalakshmi 59 F 160 1 
13 S. Duraipandi 37 M 310 1 
14 Thirunangai 55 F 304 1 
15 Jaya 46 F 139 1 
16 V. Sundarrajan 43 M 218 2 
17 Vallaiammal 64 F 163 2 
18 Mallikam 54 F 300 2 
19 Seetha 57 F 137 1 
20 Sangavi 75 M 126 2 
21 Usha 40 F 186 3 
22 Arjunan 41 M 325 1 
23 Masilamani 66 M 185 4 
24 Nagammal 68 F 320 2 
25 Baby 54 F 163 2 
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26 Paripuranam 60 F 280 4 
27 Padmavathy 49 F 240 2 
28 Nithyanandum 47 M 258 4 
29 Sampath Kumar 48 F 212 3 
30 Madhur 40 M 192 2 
31 Shantanalakshmi 60 F 179 3 
32 Manogi 40 F 150 2 
33 Charuma 30 F 200 4 
34 Saranya 50 F 150 2 
35 Akshaya 30 F 156 2 
36 Maneka 40 F 189 1 
37 Manikandan 55 M 234 3 
38 Hari 56 M 129 2 
39 Thayagraj 54 M 200 5 
40 Vimal 53 M 150 2 
 
